Peripheral Neuropathies
Neuropathies associated with cytomegalovirus infection
Nov. 16, 2024
Worddefinition
At vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas.
Meningococcal meningitis …
- Updated 05.21.2024
- Released 12.07.2004
- Expires For CME 05.21.2027
Meningococcal meningitis
Introduction
Overview
The author explains the clinical presentation, pathophysiology, diagnostic workup, and management of meningococcal meningitis. Meningococcal meningitis may be indistinguishable from other bacterial meningitides, although the classic triad of fever, neck stiffness, and change in mental status is significantly less common in patients with meningococcal meningitis (27%) than in patients with pneumococcal meningitis (58%). Although less than one third of affected patients present with the classic triad of fever, nuchal rigidity, and change in mental status, nearly 90% have at least two of the following four signs on presentation: fever, nuchal rigidity, change in mental status, and rash. Guidelines for use of the various meningococcal vaccines are summarized.
Key points
|
• Meningococcemia presents abruptly with fever, chills, nausea, vomiting, headache, myalgias, malaise, prostration, and rash. Rash is somewhat variable and may be urticarial, maculopapular, or petechial. | |
|
• Acute fulminating cases of meningococcal septicemia (Waterhouse-Friderichsen syndrome) occur mainly in children younger than 10 years of age and are characterized by vomiting, diarrhea, extensive purpura, disseminated intravascular coagulation, cyanosis, convulsions, shock, coma, and often death within hours despite appropriate treatment; many of these cases have meningitis and adrenal insufficiency with hemorrhage into the adrenal glands or adrenal infarction. | |
|
• Meningococcal meningitis may be indistinguishable from other bacterial meningitides, although the classic triad of fever, neck stiffness, and change in mental status is significantly less common in patients with meningococcal meningitis (27%) than in patients with pneumococcal meningitis (58%). | |
|
• Although less than one third of affected patients present with the classic triad of fever, nuchal rigidity, and change in mental status, nearly 90% have at least two of the following four signs on presentation: fever, nuchal rigidity, change in mental status, and rash. | |
|
• The strains of Neisseria meningitidis most commonly implicated in systemic disease are A, B, C, W, and Y. In the United States, groups B, C, and Y are the most common serogroups implicated, and each account for about 30% of reported cases. | |
|
• North American outbreaks (as opposed to isolated cases) are confined primarily to serogroup C (less commonly to Y and W), although the frequency of serogroup Y outbreaks increased markedly during the 1990s. | |
|
• Although disease rates are highest among children younger than 2 years of age, almost two thirds of meningococcal disease in the United States occurs in those older than 10 years. Most cases (95% to 98%) are sporadic. However, meningococcal disease outbreaks have been occurring with increasing frequency in the United States. | |
|
• Meningococcal disease outbreaks are particularly likely to occur in semi-closed communities, such as daycare centers, schools, colleges, nursing homes, and military recruit camps. | |
|
• Almost all secondary cases in an outbreak occur within 8 days of the index case. | |
|
• The U.S. Centers for Disease Control and Prevention recommends routine vaccination with quadrivalent meningococcal conjugate vaccine of adolescents 11 to 18 years of age and vaccination of persons 2 to 55 years of age who have an increased risk of invasive meningococcal disease. | |
|
• The case-fatality ratio for meningococcal disease is approximately 10%, and 11% to 26% of survivors have serious sequelae, including neurologic disability (eg, focal neurologic deficits, seizures, etc.), limb loss, and deafness. | |
|
• Because of the risks of severe morbidity and death, appropriate antibiotic therapy should be rapidly initiated in patients suspected of having meningococcal disease. Before confirmation of meningococcal disease as the cause of the illness, empiric antibiotic coverage should be directed at the most likely pathogens based on epidemiologic considerations (eg, age, geographic location, etc.) and the known prevalence of antibiotic resistance for these organisms. No investigations should delay initiating antibiotic therapy once the diagnosis of meningococcal meningitis is suspected. | |
|
• Children who have suspected bacterial meningitis or meningococcal disease should be immediately treated with intravenous ceftriaxone, with the addition of amoxicillin or ampicillin for children younger than 3 months and the addition of vancomycin for those who have recently traveled outside of the country or who have had prolonged or multiple exposures to antibiotics. | |
|
• Recommendations for initial empiric antimicrobial therapy in adults with community-acquired bacterial meningitis are vancomycin plus a third-generation cephalosporin (eg, cefotaxime or ceftriaxone) for those aged 16 to 50 years and vancomycin plus a third-generation cephalosporin plus ampicillin for those older than 50 years, or for those with alcoholism or altered immune status. Generally, combination therapy should be continued until in vitro susceptibility testing results are available. |
Historical note and terminology
Neisseria is a large genus of bacteria that colonize the mucosal surfaces of many animals. The genus is named after German physician Albert Ludwig Sigesmund Neisser (1885-1916), who discovered Neisseria gonorrhoeae in 1879. Of the 11 species of Neisseria that colonize humans, only two are pathogens: N. meningitidis (meningococcus) and N. gonorrhoeae. Neisseria species are gram-negative bacteria included among the proteobacteria. N. meningitidis is an aerobic or facultative anaerobic, non-motile, gram-negative, diplococcal bacterium that exclusively infects humans. Neisseria diplococci resemble coffee beans when viewed microscopically.
Meningococcal disease was first described by Geneva physician Gaspard Vieusseux (1746-1814) during an outbreak in Geneva in 1805. Another outbreak was described in 1806 in New Bedford, Massachusetts by Lothario Danielson (1765-1841), a Revolutionary War veteran, and Elias Mann (1778-1807). In 1884, Italian pathologists Ettore Marchiafava (1847-1935) and Angelo Celli (1886-1914) described intracellular micrococci in cerebrospinal fluid. In 1887, Austrian pathologist and bacteriologist Anton Wiechselbaum (1845-1920), working in Vienna, identified the meningococcus (designated as Diplococcus intracellularis meningitidis) in cerebrospinal fluid and established the connection between the organism and epidemic meningitis.
-
Austrian pathologist and bacteriologist Anton Wiechselbaum (1845-1920)
Wiechselbaum identified the meningococcus (designated as Diplococcus intracellularis meningitidis) in cerebrospinal fluid and established the connection between the organism and epidemic meningitis. (Courtesy of the U.S. Nation...
At the beginning of the twentieth century, the meningococcus was recognized as a habitant of the nasopharynx of healthy individuals, particularly at camps for military recruits.
Serum therapy was developed by German physiologist Emil von Behring (1854-1917) and German physician-scientist Paul Ehrlich (1854-1915) in the late 19th century to treat diphtheria. They had produced their diphtheria serum by repeatedly injecting the bacterial toxin into a horse. The serum was then used effectively during an epidemic in Germany. A chemical company offered a contract to both men, but Behring took the considerable financial rewards for himself. Behring was controversially awarded a solo Nobel Prize in Physiology or Medicine for this in 1901, but Ehrlich earned the 1908 Nobel Prize in Physiology or Medicine for his contributions to immunology. Commercial production of diphtheria serum depended at the time on injecting an increasing number of horses with the toxin to supply demand for the serum, which resulted in caricatures of the process in the mass media of the time (albeit inappropriately crediting Behring as the sole developer.
The development of serum therapy paved the way for its application to meningococcal disease. Several investigators reported beneficial effects of serum therapy in animals from 1905 to 1907, and some among these began human experiments. An early effective serum therapy for meningococcal disease was introduced by Simon Flexner (1863-1946) at the Rockefeller Institute for Medical Research (where he was the director).
Sulfonamides were introduced in 1937, but the emergence of resistance to sulfonamides in the 1960s stimulated the development of the first vaccines against meningococci.
In the first decade of the 20th century, untreated meningococcal meningitis had a case-fatality rate of 70% to 80% (181; 202). Following the introduction of intrathecal equine meningococcal antiserum in 1913, the case-fatality rate dropped to 20% to 31% by the late 1920s and early 1930s (202). In the 1930s, with the introduction of sulfonamides, the case-fatality rate dropped to 5% to 15%. Later therapies included high-dose penicillin and third-generation cephalosporins, but the case-fatality rate has generally stayed around 6% to 14% (41; 22; 35; 202; 220; 19; 158; 196; 115; 160; 189; 193).
Meningococcal meningitis continues to be a major cause of morbidity and mortality around the world and a significant contributor to healthcare costs, even in developed countries (158; 11; 67).
Clinical manifestations
Presentation and course
|
• Invasive meningococcal disease most commonly presents with meningitis or meningococcemia, which may rapidly progress to purpura fulminans, shock, and death. | |
|
• Meningococcemia presents abruptly with fever, chills, nausea, vomiting, headache, myalgias, breathing difficulty, malaise, prostration, and rash. | |
|
• Acute fulminating cases of meningococcal septicemia (Waterhouse-Friderichsen syndrome) occur mainly in children younger than 10 years of age and are characterized by vomiting, diarrhea, extensive purpura, disseminated intravascular coagulation, cyanosis, convulsions, shock, coma, and often death within hours despite appropriate treatment; many of these cases have meningitis and adrenal insufficiency with hemorrhage into the adrenal glands or adrenal infarction. | |
|
• Meningococcal meningitis may be indistinguishable from other bacterial meningitides, although the classic triad of fever, neck stiffness, and change in mental status is significantly less common in patients with meningococcal meningitis than in patients with pneumococcal meningitis. | |
|
• Most children with meningococcal meningitis have only nonspecific symptoms in the first 4 to 6 hours but may be close to death by 24 hours after onset. |
Invasive meningococcal disease most commonly presents with meningitis or meningococcemia, which may rapidly progress to purpura fulminans, shock, and death (38; 22). In a French study of invasive meningococcal disease spanning the years 2014 to 2016, most adult cases presented as meningococcal meningitis (59%), whereas the remainder presented with meningococcemia (25%), both (9%), or other and unspecified (7%) (107).
Meningococcemia may present abruptly with fever, chills, nausea, vomiting, headache, myalgias, breathing difficulty, malaise, prostration, and rash. Rash is non-blanching but somewhat variable and may be urticarial, maculopapular, or petechial. In darker-skinned people, rash may be less evident, so it is important to check the soles of the feet, the palms, and the conjunctivas (225). Limb pain with pale or cyanotic, cold extremities, hypotension, tachycardia, and prolonged capillary refill are clinical features that indicate impending shock (225). Acute fulminating cases of meningococcal septicemia (Waterhouse-Friderichsen syndrome) occur mainly in children younger than 10 years of age and are characterized by vomiting, diarrhea, extensive purpura, disseminated intravascular coagulation, cyanosis, convulsions, shock, coma, and often death within hours despite appropriate treatment; many of these cases have meningitis and adrenal insufficiency with hemorrhage into the adrenal glands or adrenal infarction.
At initial contact, fever is present in about three quarters of the cases, whereas specific symptoms, such as headache (about one third), a rash or petechiae (about one quarter), and stiffness of the neck (about one tenth), are infrequent (105). The rash may become widespread with erythematous patches or develop into bleeding spots under the skin (petechiae, ecchymoses, or purpura). There may be associated swelling, muscle pain, skin deterioration, or gangrene in the arms and legs.
Severe complications include purpura fulminans with cutaneous pain, extensive necrosis caused by disseminated intravascular coagulation, and gangrenous necrosis of the limbs. The gangrenous areas may necessitate amputation, which may involve multiple limbs.
Meningococcal meningitis may be indistinguishable from other bacterial meningitides, including Kernig and Brudzinski signs, although the classic triad of fever, neck stiffness, and change in mental status is significantly less common in patients with meningococcal meningitis (27%) than in patients with pneumococcal meningitis (58%) (220; 100).
-
Brudzinski sign: knee flexion on attempted passive flexion of the neck in a girl with meningitis
(Source: Koplik H. The diseases of infancy and childhood designed for the use of students and practitioners of medicine. Fourth edition. Philadelphia and New York: Lea & Fibinger, 1918. Image edited and restored by Dr. Doug...
Although less than one third of affected patients present with the classic triad of fever, nuchal rigidity, and change in mental status, nearly 90% have at least two of the following four signs on presentation: fever, nuchal rigidity, change in mental status, and rash (100). Other manifestations may include headache, photophobia, nausea, vomiting, focal neurologic findings, Kernig and Brudzinski signs, a bulging fontanelle (in children under 2 years of age), stroke, seizures, and stupor or coma (35; 219; 225). A depressed level of consciousness may indicate altered blood flow, cerebral edema, and raised intracranial pressure. Stroke due to meningococcal meningitis can result from septic arteritis, venous thrombophlebitis, or thromboembolic events (221; 222). Meningitis can have a slower onset in infants, without nuchal rigidity, but with a bulging fontanelle and nonspecific clinical findings (181).
Associated with nuchal rigidity is a characteristic contraction of neck and back muscles that sometimes develops into frank opisthotonos and is often associated with hip flexion (194; 119; 92). In extreme cases, this may progress to decerebrate posturing.
-
Meningococcal meningitis, neck and back extension, and hip flexion in an infant
(Source: Smith JL. Cerebro-spinal fever. In: Keating JM, editor. Cyclopaedia of the diseases of children: medical and surgical: the articles written especially for the work by American, British, and Canadian authors. Vol. 1. Ph...
-
Meningococcal meningitis, nuchal rigidity, opisthotonus, and characteristic arm position in 8-month-old infant
(Source: Koplik H. The diseases of infancy and childhood designed for the use of students and practitioners of medicine. Fourth edition. Philadelphia and New York: Lea & Fibinger, 1918. Image edited and restored by Dr. Doug...
-
Risus sardonicus and decerebrate posturing in a 7-month-old girl with meningococcal meningitis
Children's Hospital of Philadelphia. (Source: Griffith CP. The diseases of infants and children. Vol. 1. Philadelphia, London: WB Saunders Company, 1919. Image edited and restored by Dr. Douglas J Lanska.)
|
[C]ontraction is most marked in muscles of the nucha [back of the neck], causing retraction of the head, but it is also common in the posterior muscles of the trunk, causing opisthotonus, and in less degree in those of the abdomen and lower extremities, and hence the flexed position of the thigs and legs, in which [position] patients obtain most relief. ... Attempts to overcome the rigidity, as by bringing forward the head, are very painful, and cause the patient to resist. ... The usual position of the patient in bed, in a typical or marked case, is with the head thrown back, the thighs and legs flexed, with or without [back extension]. | |
|
(194) |
In infants younger than 6 months of age, initial symptoms are typically fever and decreased activity. Seizures occur in the majority whereas a petechial or purpuric rash develops in only about one third (106).
Most children have only nonspecific symptoms in the first 4 to 6 hours but may be close to death by 24 hours after onset. Early symptoms of sepsis (eg, leg pains, cold hands and feet, and abnormal skin color) are present in nearly three quarters (72%) of children with meningococcal disease, are common presenting symptoms, and herald progression to shock. Signs of shock include tachycardia, hypotension, toxic or moribund state, depressed level of consciousness, breathing difficulty, poor urine output, leg pain, cold extremities with unusual skin color, and prolonged capillary refill time (longer than 2 seconds) (225). In children particularly, the classic features of hemorrhagic rash, meningeal signs, and impaired consciousness develop late (with median onset between 13 and 22 hours) (211).
Meningococci can also cause other organ involvement, including vasculitis, conjunctivitis, endophthalmitis, otitis media, epiglottitis, pleurisy, pneumonia, myocarditis, pericarditis, urethritis, and arthritis. Pneumonia is more common with serogroups Y and W meningococcal disease than with other serotypes (37; 181).
Prognosis and complications
The case-fatality ratio for meningococcal disease is approximately 10% (general range from 6% to 14% though values as high as 17% have been reported for New York City from 1989 to 2000), and 11% to 26% of survivors have serious sequelae (76; 111; 36; 41; 185; 153; 35; 220; 19; 158; 196; 115; 160; 189; 193; 100; 103; 156).
The continued high case fatality is largely due to the rapid disease onset in susceptible hosts. Deaths typically occur within the first 24 hours of hospitalization and are generally associated with septic shock and severe cardiovascular and coagulation disturbances (35; 100). Mortality is significantly higher for meningococcal bacteremia (17%) than for meningococcal meningitis (approximately 3%) (185; 100). Risk factors for an unfavorable outcome include serogroup C infection, infants, young adult or college student status, advanced age, rapid progression with symptoms less than 24 hours, absence of rash or rash with more than 50 petechiae, low score on the Glasgow Coma Scale on admission, tachycardia, positive blood culture, severe septicemia with hypotension, elevated erythrocyte sedimentation rate, thrombocytopenia, acidosis, and a low cerebrospinal fluid white-cell count (220; 74; 196; 189; 193).
Long-term morbidities associated with bacterial meningitis and meningococcal septicemia include headache, hearing loss, neurologic disability (eg, focal neurologic deficits, seizures, cognitive impairment, etc.), neurodevelopment problems, renal failure, limb loss, skin complications (including scarring from necrosis), orthopedic problems (damage to bones and joints), and psychosocial problems (35; 100; 225; 224; 12; 77). In a systematic review, major sequelae (eg, cognitive deficit, bilateral hearing loss, seizures, motor deficit, visual impairment, hydrocephalus) occurred in approximately 7% of patients with meningococcal meningitis, with the risk greater in low-income countries (78). However, even in serogroup B meningococcal disease, which is the commonest cause of meningitis and septicemia in high-income countries, about one tenth of survivors have major disabling deficits, and more than one third have deficits in physical, cognitive, and psychological functioning (224). Chronic hearing impairment is the most common major sequela of meningococcal meningitis (78) and occurs in 8% to 15% of survivors (35; 100).
Biological basis
|
• Neisseria meningitidis is an aerobic gram-negative diplococcus with 13 different serogroups based on the antigenic characteristics of its capsular polysaccharide (ie, A, B, C, D, 29E, H, I, K, L, W-135, X, Y, and Z). | |
|
• The strains most commonly implicated in systemic disease around the world are A, B, C, W, X, and Y. In the Americas, groups B, C, and Y are the most common serogroups implicated, and each account for about 30% of reported cases. | |
|
• Historically, serogroup A has been most often associated with epidemics in sub-Saharan Africa and also in Asia, but serogroup C was also an important cause of outbreaks in Africa in the 1980s, and serogroup W and X have emerged as causes of significant epidemics in selected African countries since 2000. | |
|
• Mandatory meningococcal vaccination with the quadrivalent (A,C,Y,W) vaccine has prevented pilgrimage-associated meningococcal outbreaks and significantly reduced the incidence of the disease during the Hajj. | |
|
• Neisseria meningitidis commonly colonizes the upper respiratory tract, particularly the microvillous surface of nonciliated columnar mucosal cells in the nasopharynx. | |
|
• Bacterial outer membrane components are related to meningococcal adhesion and invasion. | |
|
• Following pilus-mediated adhesion to human brain endothelial cells, N meningitidis initiates signaling cascades, which facilitate opening of intercellular junctions, allowing meningeal colonization. | |
|
• N meningitidis uses multiple mechanisms to evade host defenses and avoid being killed by antimicrobial proteins, phagocytes, and the complement system. | |
|
• Serum bactericidal activity is dependent on the complement system (especially C2 and C5) and high antibody titers. | |
|
• After Neisseria meningitidis infection, convalescent patients develop a natural long-lasting cross-protective immunity. |
Etiology and pathogenesis
Neisseria meningitidis. Neisseria meningitidis is an aerobic gram-negative diplococcus with 13 different serogroups based on the antigenic characteristics of its capsular polysaccharide (ie, A, B, C, D, 29E, H, I, K, L, W-135, X, Y, and Z). The W-135 and 29E serogroup designations originated at the Walter Reed Army Institute of Research in the 1960s but were renamed as serogroups W and E, respectively, because the numbers are historic and supply no useful information (80; 98).
The strains most commonly implicated in systemic disease around the world are A, B, C, W, X, and Y (96). In the Americas, groups B, C, and Y are the most common serogroups implicated, and each account for about 30% of reported cases (180; 153; 117). North American outbreaks (as opposed to isolated cases) are confined primarily to serogroup C (less commonly to Y and W), although the frequency of serogroup Y outbreaks increased markedly during the 1990s (36; 37; 180; 120; 216; 153; 95; 229). Serogroups B and C are responsible for most cases in Europe (22; 104; 117), whereas serogroups A, C, and W135 predominate in Asia and Africa (117; 10).
Historically, serogroup A has been most often associated with epidemics in sub-Saharan Africa and also in Asia, but serogroup C was also an important cause of outbreaks in Africa in the 1980s, and serogroup W and X have emerged as causes of significant epidemics in selected African countries since 2000 (233; 89; 209; 123; 109; 122; 154; 235). Meningitis epidemics occur annually in Africa during the dry season (January to May) and stop with the first rains (123). Serogroup W caused significant epidemics in Burkina Faso and Niger in 2001 and 2002 (205; 69; 209; 229). Although serogroup X had been a rare cause of meningitis, serogroup X was responsible for significant outbreaks of meningococcal disease in Niger, Uganda, Kenya, Togo, and Burkina Faso from 2006 to 2010 (21; 235). After gradual introduction of mass vaccination with a monovalent meningococcal A conjugate vaccine beginning in 2010, serogroup A epidemics have been eliminated (31; 07; 32). However, serogroup C, W, and X meningococci continue to circulate in African meningitis belt countries and have been responsible for focal epidemics (07; 62; 81; 177; 192). Starting in 2013, the acquisition of capsule genes and virulence factors by a strain previously circulating asymptomatically in the African population led to the emergence of a virulent strain of serogroup C Neisseria meningitidis in Niger and Nigeria (31).
Mandatory meningococcal vaccination with the quadrivalent (A,C,Y,W) vaccine has prevented pilgrimage-associated meningococcal outbreaks and significantly reduced the incidence of the disease during the Hajj (236). Serogroup W emerged as an important cause of meningococcal epidemics in Saudi Arabia, especially during the Hajj, the annual Islamic pilgrimage to Mecca (Makkah) (203; 136).
By multilocus electrophoresis, hundreds of different electrophoretic types have been identified among invasive isolates, but less than 10 “hyperinvasive lineages” are responsible for most meningococcal disease worldwide (22; 199). Most strains are not pathogenic (181; 22; 199).
Colonization of the upper respiratory tract. Neisseria meningitidis commonly colonizes the upper respiratory tract and, particularly, the microvillous surface of non-ciliated columnar mucosal cells in the nasopharynx (181). Meningococcal carriage prevalence increases through childhood from approximately 5% in infants to a peak of 24% at 19 years of age and subsequently decreases in adulthood to 8% by 50 years of age (54).
Following acquisition, N meningitidis must compete against host defenses and interactions with other microbiome members to inhabit the nasopharynx mucus (149). Pathogenic meningococci associated with invasive disease have a capsule, which protects the bacteria from desiccation and host-mediated, complement-dependent bacteriolysis and phagocytosis (181). Eventual binding of N meningitidis to the epithelial surface of the nasopharynx results in passage into the submucosa by transcytosis. Binding of N meningitidis to epithelial cells occurs by interaction of bacterial surface structures with their cognate receptors, resulting in inflammation, cellular restructuring, and transcytosis (149).
Evading host defenses. To survive in the bloodstream and proceed to transcellular invasion, N meningitidis must avoid or resist antibody- and complement-mediated killing, acquire iron, and attach to the capillary endothelial surface to form microcolonies (149).
N meningitidis uses multiple mechanisms to evade host defenses and avoid being killed by antimicrobial proteins, phagocytes, and the complement system (126; 96; 127). Such strategies include mimicry of host molecules by bacterial structures (eg, capsular proteins) as well as frequent antigenic variation (126; 96; 103). The mechanisms involved in meningococcal immune evasion and resistance against complement increase in response to an increase in ambient temperature (eg, with inflammation); the increased temperature acts as a “danger signal” for the meningococcus, which responds by enhancing its defense against human immune killing (127). Unfortunately, continuous adaptation of meningococcal surface structures has produced genetic shifts of potential vaccine-target epitopes, impeding development of a universal meningococcal vaccine that could be used against all serogroups, especially serogroup B (126; 103). In addition, the alpha-2,8-linked polysialic acid capsule modifies the interaction of serogroup B meningococci with human macrophages at multiple steps, including adherence to the macrophage surface and phagosome-lysosome fusion (176).
Meningococcal adhesion and invasion. Like the binding of N meningitidis to the epithelial surface of the nasopharynx, binding of N meningitidis to endothelial cells occurs by interaction of meningococcal surface structures with their cognate receptors, resulting in cortical plaque formation, transcytosis, and breakdown of tight junctions (149).
Binding of endothelial cells occurs by interaction of meningococcal surface structures with their cognate receptors
Binding of endothelial cells occurs by interaction of meningococcal surface structures with their cognate receptors, resulting in cortical plaque formation, transcytosis, and breakdown of tight junctions. (Source: Mikucki A, Mc...
Bacterial outer membrane components are related to meningococcal adhesion and invasion. Bacterial capsular adhesion molecules (including pili and opacity-associated proteins Opa and Opc) are responsible for binding specific human membrane proteins.
Bacterial type IV pili—long retractile fibers with a diameter of 6 nm—are necessary both for adhesion to human cells and for plasma membrane remodeling (53). Remodeling of the plasma membrane of endothelial cells by N meningitidis during the blood phase of meningococcal infection is tightly linked to the amount of type IV pili expressed by the bacteria. Plasma membrane remodeling occurs independently of F-actin, along meningococcal type IV pili fibers (53).
-
Scanning electron micrograph of a single N. meningitidis cell with its dense meshwork of pili
Scanning electron micrograph of a single N meningitidis cell (colorized in blue) with its dense meshwork of pili (colorized in yellow). The scale bar is 1 μm. (Courtesy of Arthur Charles-Orszag, adapted by him from: Ch...
-
Scanning electron micrograph of an endothelial cell infected for 10 minutes infection with N. meningitidis
Arrowheads show plasma membrane protrusions. Scale bar, 500 nm. (Source: Charles-Orszag A, Tsai FC, Bonazzi D, et al. Adhesion to nanofibers drives cell membrane remodeling through one-dimensional wetting. Nat Commun 2018;9[1]:...
-
Scanning electron micrograph of an endothelial cell after infection with N. meningitidis (1)
Colorized crop shows plasma membrane protrusions (magenta, dotted lined) attached alongside bacterial type IV pili (yellow). Bacterial type IV pili have been stabilized with a monoclonal antibody. Abbreviation: T4P, bacterial t...
-
Scanning electron micrograph of an endothelial cell after infection with N. meningitidis (2)
Bacterial type IV pili have been labeled with immunogold. Bacterial type IV pili have been stabilized with a monoclonal antibody and labeled with immunogold. Abbreviations: Protr, protrusions; T4P, bacterial type IV pili. Scale...
-
Transmission electron micrograph of a microcolony of N. meningitidis after high pressure freezing and freeze substitution (1)
Transmission electron micrograph shows plasma membrane protrusions embedded in a meshwork of bacterial type IV pili. Abbreviation: T4P, bacterial type IV pili. Scale bars, 200 nm. (Source: Charles-Orszag A, Tsai FC, Bonazzi D, ...
-
Transmission electron micrograph of a microcolony of N. meningitidis after high pressure freezing and freeze substitution (2)
Transmission electron micrograph shows plasma membrane protrusions embedded in a meshwork of bacterial type IV pili labeled with immunogold. Abbreviation: T4P, bacterial type IV pili. Scale bars, 200 nm and 50 nm. (Source: Char...
N meningitidis produces type IV pili as a meshwork of fibers. On adhesion to the host endothelial cell, the high adhesiveness of type IV pili enables "one-dimensional membrane wetting" of the plasma membrane, thus, remodeling the membrane alongside the type IV pili fibers. As the bacteria proliferate and aggregate extracellularly, plasma membrane protrusions remain attached to type IV pili fibers and end up embedded in a dense extracellular type IV pili meshwork that provides the microcolony with sufficient mechanical coherence to resist blood flow–generated shear stress (53).
Working model of the mechanism of wetting-induced plasma membrane protrusions by N. meningitidis type IV pili fibers
N meningitidis produces type IV pili as a meshwork of fibers. On adhesion to the host endothelial cell, the high adhesiveness of type IV pili allows “one-dimensional” membrane wetting of the plasma membrane and, thus, ...
Expression of a specific human carcinoembryonic antigen-related cell adhesion molecule (CEACAM1) is necessary for binding the neisserial Opa protein adhesions, and for establishing intranasal colonization with Neisseria meningitides (114). Binding stimulates bacterial engulfment by mucosal epithelial cells, and subsequent passage of bacteria through the mucosa in phagocytic vacuoles (181). Meningococcal vascular adhesion is restricted to capillaries that exhibit transient reductions in flow (131). Initial adhesion of pathogenic strains of Neisseria meningitidis to endothelial cells relies on meningococcal type IV pili (17). The immunoglobulin superfamily member CD147, which is also known as extracellular matrix metalloproteinase inducer (EMMPRIN), is a critical host receptor for the meningococcal pilus components PilE and PilV (17). Interrupting the interaction of this endothelial receptor for bacterial adhesion potently inhibits the attachment of meningococci to human endothelial cells in vitro and prevents colonization of vessels in human brain tissue explants ex vivo and in mice in vivo (17).
Following pilus-mediated adhesion to human brain endothelial cells, N meningitidis initiates signaling cascades, which facilitate opening of intercellular junctions, allowing meningeal colonization (65). N meningitidis specifically stimulates a beta-2-adrenoceptor/beta-arrestin signaling pathway in endothelial cells, which traps beta-arrestin-interacting partners (eg, the Src tyrosine kinase and junctional proteins) under bacterial colonies; these in turn mediate cytoskeletal reorganization, which stabilizes bacterial adhesion to endothelial cells, and produce anatomical gaps used by bacteria to penetrate into tissues (65). Mutations in the N meningitidis surface-exposed proteins glyceraldehyde 3-phosphate dehydrogenase (GapA-1) and fructose-1, 6-bisphosphate aldolase also significantly affect the ability of the bacterium to adhere to human epithelial and endothelial cells (214; 215).
During meningococcal sepsis, Neisseria meningitidis accumulates in large organs (29).
Genetic traits of Neisseria meningitidis linked to phenotypic outcomes (ie, invasive meningococcal disease or carriage) have been identified (79): one gene and one non-synonymous single nucleotide polymorphism (SNP) were associated with invasive disease, and seven genes and one non-synonymous SNP were associated with carriage isolates. The gene associated with invasive disease encodes a phage transposase (NEIS1048), and the associated invasive SNP glmU S373C encodes the enzyme N-acetylglucosamine 1-phosphate (GlcNAC 1-P) uridyltransferase. In the genes fkbp, glmU, PilC, and pilE, k-mers were found that were associated with both carriage and invasive isolates, indicating that specific variations within these genes could play a role in invasiveness.
Bacterium-host interactions. Bacterium-host interactions are key determinants of the clinical course and risk of fatal outcomes. The interaction of meningococci with host endothelial cells is mediated by type IV pili, which are responsible for the formation of microcolonies on the apical surfaces of the cells (pili are hairlike appendages on the bacterial surface, and type IV pili, in particular, can generate motile forces that can pull the bacteria forward like a grappling hook, so-called twitching motility) (64). A low level of bacteremia favors colonization of brain blood vessels and development of meningitis, whereas colonization of many blood vessels during high-level bacteremia results in septic shock and purpura fulminates (64). In the bloodstream, meningococci release a lipo-oligosaccharide endotoxin (structurally distinct from the endotoxin of enteric gram-negative bacteria) and other cell-wall components, which stimulate cytokine production and induce the inflammatory cascade (181). Toll-like receptor 9 (TLR9) recognizes bacterial DNA leading to intracellular inflammatory signaling, and specific TLR9 single nucleotide polymorphisms are associated with susceptibility to meningococcal meningitis (183).
High-frequency changes have been identified in pilin glycosylation patterns during Neisseria meningitidis serogroup A meningitis outbreaks in the African meningitis belt, which suggests that variation in N meningitidis protein glycosylation could be crucial for bacterial adaptation to evade herd immunity in semi-immune populations (112).
Serum bactericidal activity is dependent on the complement system (especially C2 and C5) and high antibody titers (101; 206). Therefore, terminal complement component defects and alterations in complement regulators are associated with an increased risk of developing N meningitidis infections (101). The polysaccharide capsule protects against complement-mediated bacterial killing, opsonization, and phagocytosis (206). In addition, during invasive disease, N meningitidis releases the contents of outer membrane vesicles into the bloodstream: these contents include lipo-oligosaccharide and outer-membrane proteins that confound the immune response to the bacteria (206).
After N meningitidis infection, convalescent patients develop a natural long-lasting cross-protective immunity, but the antigens that mediate this response have not been fully identified (147). One potential such antigen, GNA2132, is an N meningitidis protein of unknown function discovered by reverse vaccinology (188). GNA2132 has been shown to induce bactericidal antibodies in animal models, to induce protective immunity in humans, and to be recognized by sera of patients after meningococcal disease; because the protein binds heparin in vitro and because this property correlates with increased survival of the unencapsulated bacterium in human serum, the protein was renamed “Neisserial heparin binding antigen.”
Alternate routes of entry into CNS. N meningitidis readily infects trigeminal Schwann cells (the glial cells of the trigeminal nerve) (71). Infection of trigeminal Schwann cells may be one mechanism by which N meningitidis can invade the CNS. Infection of trigeminal Schwann cells leads to multinucleation and the appearance of atypical nuclei, with progressive increases over time in the presence of horseshoe nuclei and the budding of nuclei (71).
Meningitis and secondary brain complications. Meningococcal meningitis produces a purulent exudate over the surface of the brain and spinal cord. Leptomeningeal inflammatory infiltrates consist of neutrophilic granulocytes.
-
Purulent exudate over the convexity of the brain in a fatal case of meningococcal meningitis
Note how the sulci are obscured by the exudate. (Source: Koplik H. The diseases of infancy and childhood designed for the use of students and practitioners of medicine. Fourth edition. Philadelphia and New York: Lea & Fibin...
-
Purulent exudate over the lateral surface of the brain in a fatal case of meningococcal meningitis
Note how the sulci are obscured by the exudate. (Source: Koplik H. The diseases of infancy and childhood designed for the use of students and practitioners of medicine. Fourth edition. Philadelphia and New York: Lea & Fibin...
-
Epidemic meningococcal meningitis in an adult, with death on the fifth day of illness (spinal cord section)
Section of the spinal cord, showing the purulent exudate on the surface, more marked posteriorly and involving the anterior and posterior nerve roots. (Source: Koplik H. The diseases of infancy and childhood designed for the us...
The inflammatory response produced to eradicate infectious pathogens can have further negative consequences, including ischemic stroke. Bacterial virulence factors and pathogen-associated molecular reactions cause direct damage to the blood-brain barrier and activate leukocytes to respond to the infection. Cytokine release further damages the blood-brain barrier, leads to neuronal death, and activates the coagulation cascade through the complement system. This inflammatory response causes vasculopathy and promotes coagulation of cerebral blood vessels, leading to cerebral ischemia.
Epidemiology
|
• Humans are the only natural reservoir of Neisseria meningitidis. | |
|
• N meningitidis is essentially a human commensal, with most infections producing harmless nasopharyngeal colonization rather than invasive disease. | |
|
• Most cases of meningococcal invasive disease occur in children and young adults. | |
|
• Worldwide, there are 1.2 million cases of invasive meningococcal disease, with some 135,000 deaths annually. | |
|
• The vast majority of cases (95% to 98%) of invasive meningococcal disease are sporadic. | |
|
• Periodic outbreaks of meningococcal disease have been persistent problems in specific geographical areas, including the “meningitis belt” of sub-Saharan Africa. | |
|
• In non-African countries over the 50 years from 1966 to 2017, the predominant serogroup in most outbreaks was serogroup C. | |
|
• Serogroups B, C, and Y are the major causes of meningococcal disease in the United States, with each responsible for about one third of cases. | |
|
• Meningococcal disease is the leading infectious cause of death in early childhood. | |
|
• Even though the incidence of invasive meningococcal disease is declining in some populations, there has been a countermining trend of decreasing rates of penicillin susceptibility. | |
|
• In the “meningitis belt” of sub-Saharan Africa, outbreaks of serogroup A meningitis usually start in the dry season. | |
|
• Prior attempts to control epidemic meningococcal meningitis in Africa by vaccination with meningococcal polysaccharide vaccines were not successful because polysaccharide vaccines are poorly immunogenic in young children, do not induce immunological memory, and do not significantly alter pharyngeal carriage. | |
|
• With the reduction in the incidence of serogroup A meningococcal meningitis in the meningitis belt as a result of mass meningitis vaccination specific to that serogroup, there has been so-called “serogroup replacement” with an increase in the incidence of serogroups W, X, and C, and also an increase in pneumococcal meningitis. | |
|
• In the African meningitis belt, carriers of Neisseria meningitidis are a key source of transmission. |
Humans are the only natural reservoir of Neisseria meningitidis. N meningitidis is essentially a human commensal, with the great majority of infections producing harmless nasopharyngeal colonization rather than invasive disease (104; 199; 126; 103; 206). Meningococci are transmitted person-to-person through respiratory droplets. Nasal carriage rates average about 8% to 15% (84; 181), but some studies report yields of more than 30% with nasopharyngeal swabs (165). There is a low prevalence of carriage in saliva (less than 1%), indicating that saliva contact is unlikely to transmit meningococci (165). Although meningococci can be transmitted throughout the year, most cases in developed countries occur during the winter and early spring (181; 160; 189).
Most cases of invasive disease occur in children and young adults (111; 185). The highest rates are among infants under 6 months of age, who have the lowest serum bactericidal antibody titers because they do not have meningococcal-specific maternal bactericidal antibodies (206). Although rates of disease are highest among children under 2 years of age (and especially in infants younger than 6 months), almost two thirds of meningococcal disease in the United States occurs in those older than 10 years. Infants under 1 year of age have the highest incidence of meningococcal disease (5.38 cases per population of 100,000) (55). Adolescents and young adults continue to have the second-highest disease incidence from N meningitidis infection (27).
Worldwide there are 1.2 million cases of invasive meningococcal disease, with some 135,000 deaths annually.
Meningococcal disease is the leading infectious cause of death in early childhood (171).
Even though the incidence of invasive meningococcal disease is declining in some populations, there has been an opposing trend of decreasing rates of penicillin susceptibility (18).
As part of the Global Burden of Disease Study 2019, the global, regional, and national burden of meningitis and its etiologies were evaluated for 1990 to 2019 (88). In 2019, there were an estimated 236,000 deaths and 2.51 million incident cases due to meningitis globally; the burden was greatest in children younger than 5 years old, with 112,000 deaths and 1.28 million incident cases. Tremendous variation exists in regional risks from meningitis in children younger than 5 years old. Age-standardized mortality rates decreased from 7.5 per 100,000 population in 1990 to 3.3 per 100,000 population in 2019. The proportion of total all-age meningitis deaths in 2019 attributable to N meningitidis was 13.6%. Between 1990 and 2019, the number of deaths due to N meningitidis among children younger than 5 years old declined by 72%, but N meningitidis still accounts for the most cases of bacterial meningitis in this age group and the second-highest number of deaths from bacterial meningitis in this age group (after Streptococcus pneumoniae).
-
Meningitis mortality rate per 100,000 population, both sexes, under 5 years, 2019
(Source: GBD 2019 Meningitis Antimicrobial Resistance Collaborators. Global, regional, and national burden of meningitis and its aetiologies, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet ...
-
Meningitis incidence rate per 100,000 population, both sexes, under 5 years, 2019
(Source: GBD 2019 Meningitis Antimicrobial Resistance Collaborators. Global, regional, and national burden of meningitis and its aetiologies, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet ...
-
Global number of meningitis deaths by etiology and age group in 1990 and 2019
(Source: GBD 2019 Meningitis Antimicrobial Resistance Collaborators. Global, regional, and national burden of meningitis and its aetiologies, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet ...
-
Global number of meningitis cases by etiology and age group in 1990 and 2019
(Source: GBD 2019 Meningitis Antimicrobial Resistance Collaborators. Global, regional, and national burden of meningitis and its aetiologies, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet ...
Risk factors for invasive meningococcal disease. Risk factors for invasive meningococcal disease are outlined in the table below (38; 40; 41; 83; 57; 181; 120; 216; 199; 232; 201; 91; 75).
Table 1. Risk Factors for Invasive Meningococcal Disease
|
• Age less than 5 years | |
|
• Blacks | |
|
• Low socioeconomic status | |
|
• Attendees at daycare centers | |
|
• College freshmen, especially dormitory residents (48) | |
|
• Military recruits (48) | |
|
• Household crowding | |
|
• Bar or nightclub patronage during community outbreaks | |
|
• Travel to countries with hyperendemic or epidemic meningococcal disease (eg, West Africa), particularly associated with the dry wind known as Harmattan during the peak months from February to May (48) | |
|
• Homelessness (13) | |
|
• Refugees and migrants (13) | |
|
• Microbiologists frequently exposed to isolates of N meningitides (48). Occupational transmission of Neisseria meningitides has also been reported in first responders and healthcare workers (49). | |
|
• Cigarette smoking, both active and passive (including maternal smoking as a risk factor for meningococcal meningitis in children) | |
|
• Other forms of smoke, including kitchen smoke in underdeveloped countries (154) | |
|
• Viral infection of the upper respiratory tract, particularly with influenza A, but also with unspecified flu-like illnesses (154) | |
|
• Chronic underlying disease | |
|
• Human immunodeficiency virus infection | |
|
• Hepatitis C virus infection | |
|
• Asplenia, functional or anatomic (48) | |
|
• Deficiencies of the complement system, including properdin deficiency (component of the alternative pathway), terminal complement component deficiency (especially C5), C2 complement deficiency, or alterations in complement regulators (184; 48; 101; 206) |
Meningococcal serogroup trends. In non-African countries over the 50-year period from 1966 to 2017, the predominant serogroup in most outbreaks was serogroup C (61%), followed by serogroup B (29%), serogroup A (5%), and serogroup W135 (4%) (223). Outbreaks showed a peak in the colder months of both the northern and southern hemispheres (223). In Eastern Europe, the predominate serogroups are B and C, followed by A, and cases attributable to serogroups W, X and Y are emerging (14; 23).
Serogroups B, C, and Y are the major causes of meningococcal disease in the United States, with each responsible for about one third of cases (19). However, the proportion of cases caused by each serogroup varies by age. Among infants, most cases are caused by serogroup B (19). In contrast, for persons older than 10 years, more than three quarters of cases are caused by serogroups C, Y, or W, all of which are included in licensed vaccines in the United States (19). In 2016, a serogroup C meningococcal disease outbreak occurred in Southern California, primarily affecting homosexual men (157).
From 2014 to 2018, 822 cases of serogroup A, C, W, and Y meningococcal disease were reported in the Netherlands, of which 34 (4%) were in patients who previously received at least one dose of MenACWY vaccine (23 were up to date on MenACWY vaccine, per recommendations) (20). A significantly higher proportion of vaccinated patients were people living with HIV compared to unvaccinated patients. Eight of the 34 vaccinated patients were immunosuppressed, including five with HIV, one taking eculizumab, and two taking other immunosuppressive medications.
Key aspects of recent global meningococcal disease epidemiology include the following: (1) Serogroups A, B, C, W, and Y remain dominant, but there have been recent global increases in serogroup W disease, meningococcal antimicrobial resistance, and meningococcal urethritis; (2) Unvaccinated populations have experienced disease resurgences following the lifting of COVID-19 restrictions; (3) Elevated invasive meningococcal disease rates are seen among infants and young children, adolescents/young adults, and older adults; and (4) Demonstrably effective vaccines against all five major disease-causing serogroups are available, and their prophylactic use is effective against invasive meningococcal disease, including cases with antimicrobial resistance (23).
United States. The incidence of meningococcal disease peaks in late winter to early spring (01). Attack rates are highest among infants 3 to 12 months of age.
The annual incidence in the United States decreased from 0.92 cases per population of 100,000 in 1998 to 0.33 cases per 100,000 in 2007 (55). Before the introduction of the quadrivalent meningococcal conjugate vaccine, the incidence of meningococcal disease in the United States decreased to a historic low, but no further significant decrease in serogroup C or Y meningococcal disease has been observed after the introduction of the quadrivalent meningococcal conjugate vaccine among those aged 11 to 19 years (ie, when assessed for 2006 to 2007, compared with 2004 to 2005) (55).
The vast majority of cases (95% to 98%) are sporadic (104; 19). However, outbreaks of meningococcal disease in the United States have been occurring with increasing frequency since 1990 (19). Meningococcal disease outbreaks are particularly likely in semi-closed communities, such as daycare centers, schools, colleges, nursing homes, and military recruit camps (22; 19). Almost all secondary cases in an outbreak occur within 8 days of the index case (104).
The emergence of beta-lactamase-positive and ciprofloxacin-resistant meningococci in the United States is a major concern (13).
In 2022, concurrent outbreaks of invasive meningococcal disease, hepatitis A, and mpox were identified in Florida, primarily among men who have sex with men (73). The invasive meningococcal disease outbreak in Florida involved 44 cases and was associated with Neisseria meningitidis serogroup C (sequence type 11, clonal complex 11). In comparison, the hepatitis A outbreak in Florida involved 153 cases and the mpox outbreak in Florida involved 2845 cases. The invasive meningococcal disease and hepatitis A outbreaks were concentrated in Central Florida and peaked from March to June, whereas the mpox cases were more heavily concentrated in South Florida and had a peak incidence in August. HIV infection was more common among mpox cases (52%) than among invasive meningococcal disease (34%) or hepatitis A (21%) cases.
-
Epidemiologic curves of concurrent outbreaks of hepatitis A and invasive meningococcal disease, United States, 2021 to 2022
Epidemiologic curves of concurrent outbreaks of hepatitis A and invasive meningococcal disease by week of symptom onset, Florida, USA, November 1, 2021 to November 30, 2022. (A) Invasive meningococcal disease; (B) hepatitis A. ...
-
Spatial distribution of outbreak-associated cases of hepatitis A and invasive meningococcal disease, United States, 2021 to 2022
Spatial distribution of outbreak-associated cases of hepatitis A and invasive meningococcal disease in an investigation of concurrent outbreaks in Florida, 2021 to 2022. (A) Locations of cases by postal (ZIP) code of patient re...
-
Vaccinations during concurrent outbreaks of hepatitis A, invasive meningococcal disease, United States, 2021 to 2022
Persons vaccinated by month and antigen during concurrent outbreaks of hepatitis A, invasive meningococcal disease, and mpox, Florida, USA, 2021 to 2022. The figure shows the number of adult persons (older than 18 years of age)...
Europe. Incidence rates are higher in Europe (1.01 per population of 100,000 per year) than in the United States, but some European countries have also documented a declining incidence of invasive meningococcal disease as a consequence of improved vaccines (particularly with the introduction of effective meningococcal conjugate vaccines in the 1990s) or broader penetration of vaccination (18; 132; 164).
Patients admitted to hospitals for invasive meningococcal disease between 2014 and 2016 were selected from the French hospital discharge database (107). Of the 1344 patients identified, about 30% of cases were in children younger than 5 years old and 25% in children aged 10 to 24 years. There is a seasonal variation in the incidence of meningococcal meningitis, with cases increasing in March and April (107). Most patients presented with meningococcal meningitis (59%), 25% with meningococcemia, and 9% with both. The case fatality rate during the index hospitalization was 6%. About 15% of patients had at least one sequela at hospital discharge.
Number of invasive meningococcal disease cases identified in France during the study period (2014–2016)
(Source: Huang L, Fievez S, Goguillot M, et al. A database study of clinical and economic burden of invasive meningococcal disease in France. PLoS One 2022;17[4]:e0267786. Creative Commons Attribution 4.0 International License,...
In Spain, the average hospitalization rate for meningococcal infection was 1.64 hospitalizations per 100,000 inhabitants from 1997 through 2018, with a significant declining trend over that interval (226). Hospitalization rates of meningococcal infection, meningococcal meningitis, and meningococcemia all declined from 1997 to 2018. Hospitalizations for meningococcal infection decreased significantly with increasing age and were concentrated in young children, with almost half (46%) in children under 5 years of age (46%). The hospitalization rates reached 29 per 100,000 and 24 per 100,000 in children under 1 and 2 years of age, respectively. The case fatality rates overall were 7.5% for meningococcal infection, 4.0% for meningococcal meningitis, and 9.6% for meningococcemia. Case fatality rates increased with increasing age. Thirty percent of the deaths occurred in children under 5 years of age, and more than half occurred in adults.
-
Hospitalization rate related to meningococcal infection, meningococcal meningitis, and meningococcemia in Spain (1997-2018)
Rates are graphed for meningococcal infection (red), meningococcal meningitis (green), and meningococcemia (blue). (Source: Walter S, Gil-Prieto R, Gil-Conesa M, Rodriguez-Caravaca G, San Román J, Gil de Miguel A. Hospitalizati...
-
Hospitalization rate related to meningococcal meningitis by age group in Spain (1997-2018)
Rates are graphed for ages less than 1 (red), less than 2 (yellow), less than 5 (green), 5 to 9 (blue), and 10 to 14 (purple). Note that the first three age groups overlap. (Source: Walter S, Gil-Prieto R, Gil-Conesa M, Rodrigu...
-
Hospitalization rate related to meningococcemia by age group in Spain (1997-2018)
Rates are graphed for ages less than 1 (red), less than 2 (yellow), less than 5 (green), 5 to 9 (blue), and 10 to 14 (purple). Note that the first three age groups overlap. (Source: Walter S, Gil-Prieto R, Gil-Conesa M, Rodrigu...
-
Case fatality rates for meningococcal infection, meningococcal meningitis, and meningococcemia in Spain (1997-2018)
(Figure by Dr. Douglas J Lanska, based on tabular data in: Walter S, Gil-Prieto R, Gil-Conesa M, Rodriguez-Caravaca G, San Román J, Gil de Miguel A. Hospitalizations related to meningococcal infection in Spain from 1997 to 2018...
In Italy, admissions for invasive meningococcal disease continue to be highest for infants, but this group has seen steady declines from 2015 to 2019 (208). The percentage of hospitalized patients who died from “meningeal syndrome” remained below 5% from 2015 to 2019, although the trend is worsening, whereas the percentage of hospitalized patients who died from “septic shock” with or without meningitis has been between 10% to 25% from 2015 to 2019, with 2019 being the worst year.
-
Incidence of admissions for invasive meningococcal disease in Italy by age group from 2015 to 2019
(Source: Tascini C, Iantomasi R, Sbrana F, et al. MAGLIO study: epideMiological Analysis on invasive meninGococcaL disease in Italy: fOcus on hospitalization from 2015 to 2019. Intern Emerg Med 2023;18[7]:1961-9. Creative Commo...
-
Percentage of hospitalized patients who died from “meningeal syndrome” or “septic shock” with or without meningitis in Italy from 2015 to 2019
(Source: Tascini C, Iantomasi R, Sbrana F, et al. MAGLIO study: epideMiological Analysis on invasive meninGococcaL disease in Italy: fOcus on hospitalization from 2015 to 2019. Intern Emerg Med 2023;18[7]:1961-9. Creative Commo...
Southeastern European countries (Croatia, the Czech Republic, Greece, Hungary, Poland, Romania, Serbia, Slovenia, and Ukraine) had lower vaccination rates than the European average (217). The age distribution of invasive meningococcal disease cases was highest in infants and children, and most of these countries also had a further peak in adolescents and young adults. Across these nine countries between 2010 and 2020, the largest contributors to invasive meningococcal disease were serogroups B and C.
Africa. The major burden of invasive meningococcal disease is in nonindustrialized countries: in particular, Africa has been, and remains, the continent most affected by invasive meningococcal disease. Formerly heavily concentrated in the region of the "meningitis belt" of sub-Saharan Africa, invasive meningococcal disease now extends outside of its historical limits, involving more forested regions in the central and southern parts of the continent (eg, Burundi, Rwanda, the Republic of Tanzania in the Greater Lakes area, and South Africa) (01; 229; 137; 143).
In Africa, in the interval from 1928 to 2018 (excluding 1948–1957, years for which data were unavailable), very high case counts (> 50,000) occurred in 1946, 1970, 1978, 1981, 1986, 1988–89, 1991–2, 1995–7, 2003, and 2009 (137). Very high death counts (> 5000) occurred in 1945–6, 1996–7, and 2003. Death counts were extremely high (> 15,000) in 1945, 1996, and 2003. Very high rates occurred in the meningitis belt but extended well beyond it during some periods (137).
-
Annual meningitis cases and deaths from meningitis, 1928 to 2018, in countries within the African meningitis belt
Bar graph of annual meningitis cases (blue bars) and deaths (blue bars) from meningitis reported from 1928 to 2018 in countries within the African meningitis belt. Note that meningitis case information is unavailable for the pe...
-
Spatial distribution of meningitis cases by country in Africa from 1928 to 2018
The areas in grey illustrate the different countries belonging to the meningitis belt. Note that meningitis case information is unavailable for the period 1948–1957. Typographical errors in the figure legend in the original hav...
Outside of the African meningitis belt, case counts were below 70,000 for all countries in the interval from 1928 to 2018 (excluding 1948–1957, years for which data were unavailable) but were highest in Ghana and RD-Congo (République démocratique du Congo, or the Democratic Republic of Congo) (137). Death counts were also highest in these two countries, although the case fatality rate was higher in RD-Congo than in Ghana.
Case counts and death counts of meningitis reported from 1928 to 2018, outside of the African meningitis belt
Bar graph of case counts (blue bars) and death counts (blue bars) of meningitis reported from 1928 to 2018 in countries outside of the African meningitis belt. Countries are ranked from left to right according to the number of ...
Among cases of meningococcal meningitis in Africa from 2000 to 2017, the most common serotypes were (in descending order) W, C, A, and X (137).
Table 2. Confirmed Cases of Meningitis and the Responsible Pathogens, Africa, 2000 to 2017
|
Pathogens |
Number of positive CSF |
Percentage |
|
Streptococcus pneumoniae |
2826 |
24.39 |
|
Haemophilus influenzae |
362 |
3.12 |
|
Neisseria meningitidis |
7747 |
66.87 |
|
Neisseria meningitidis A |
1161 |
10.02 |
|
Neisseria meningitidis B |
1 |
0.01 |
|
Neisseria meningitidis C |
2271 |
23.92 |
|
Neisseria meningitidis W |
2796 |
24.13 |
|
Neisseria meningitidis X |
552 |
4.76 |
|
Neisseria meningitidis Y |
6 |
0.05 |
|
Other Neisseria meningitidis |
460 |
3.97 |
|
Other pathogensa |
620 |
5.35 |
|
Positive Latex testa |
30 |
0.26 |
|
Total of positive CSF |
11,585 |
100.00 |
|
a Other pathogens include Streptococcus spp, Streptococcus group D, Salmonella sp, Enterobacter spp, Citrobacter spp, Staphylococcus aureus, Escherichia coli, Klebsiella sp, Candida sp, Acinetobacter sp, Listeria sp, Cryptococcus neoformans, and Pseudomonas sp (Source: WHO) | ||
|
Source: (137). Creative Commons Attribution (By 4.0) License (http://creativecommons.org/licenses/by/4.0/). | ||
Serotypes W and C together accounted for almost half (48%) of all meningitis cases in Africa in this interval, with the remainder as follows: S pneumoniae (24%), other serotypes of N meningitidis (19%), H influenza (3%), and other (5%). In Africa during the 20th century, serogroup A was responsible for up to 80% to 85% of meningococcal meningitis cases, but since 2000, other serogroups (including W, X, and C) have also been responsible for epidemics (137). The distribution of pathogens changed after the introduction of the MenAfrivac vaccine, which targeted N meningitidis serotype A (developed for use in sub-Saharan Africa for children and adults between 9 months and 29 years of age) (137). The impact of the MenAfrivac vaccine on the distribution of responsible pathogens within the African meningitis belt can also be seen spatially.
The African “meningitis belt.” Peak incidence rates of invasive meningococcal disease approach 1000 per 100,000 per year in the "African meningitis belt" of sub-Saharan Africa (144; 206). In the “meningitis belt,” outbreaks of serogroup A meningitis usually start in the dry season (28; 123; 109). Large epidemic waves occur in this area with a periodicity of 5 to 14 years, corresponding to molecular changes in the expression of capsular or subcapsular antigens (209; 109). The last large-scale meningitis epidemic in the African meningitis belt occurred in 2009 with 80,000 cases and 4300 deaths (10). During the 2013 epidemic season from January through June, there were 12,464 suspected meningitis cases and 1131 deaths (case fatality rate of 9.1%) reported from 18 African countries (10). The irregular timing of meningitis epidemics results from the interaction between changes in immunity and seasonal changes in the transmissibility of infection (109). The major virulence factor for Group A infections is a capsular polysaccharide comprised of a repeating unit of partly O-acetylated alpha-1,6-linked N-acetylmannosamine phosphate (123). Meningitis attack rates increased significantly in Africa in 2006 due to a new serogroup A strain, apparently heralding a new meningitis epidemic wave (209; 229).
In the interval from 1928 to 2018, cases and death counts varied by country, with the highest case counts (exceeding 100,000 and in descending order) in Nigeria, Niger, Burkina Faso, Soundan, and Ethiopia and the highest death counts (exceeding 10,000 and in descending order) in Burkina Faso, Niger, and Nigeria (137). Case counts exceeded 300,000 in Nigeria and Niger. Case fatality rates were extremely high in Cote d'Ivoire (Ivory Coast) and were also high in Burkina Faso, whereas case fatality was relatively low (among the worst affected countries) in Soudan and Ethiopia (easily seen visually in the graph by the relative height of death and case counts).
Case counts and death counts from meningitis reported from 1928 to 2018 in countries within the African meningitis belt
Bar graph of case counts (blue bars) and death counts (blue bars) of meningitis reported from 1928 to 2018 in countries within the African meningitis belt. Countries are ranked from left to right according to the number of case...
Since 2015, a total of 20,789 cases with 1369 fatalities (case fatality rate 6.6%) were documented in Niger (191). In contrast to earlier seasons, the outbreak of meningitis in Niger beginning in 2021 exhibited both an increase in the number of cases and a rise in the growth rate. Neisseria meningitidis serogroup C was responsible for the majority of laboratory confirmed cases (104/111; 93.7%).
Seasonal hyperendemicity in the African meningitis belt is likely predominantly caused by increased invasion rates partly due to environmental factors, such as dust and low humidity (03). Sporadic localized epidemics occur with increased transmission rates, probably related in part to human contact rates and coinfections, whereas the larger pluriannual epidemic waves result from changing population immunity. Factors that contribute to the higher transmission rates in the African meningitis belt include the dry, dusty climate; overcrowding; low standards of living; the relatively low immunocompetence of the inhabitants; and poor nutritional status of the population.
Prior attempts to control epidemic meningococcal meningitis in Africa by vaccination with meningococcal polysaccharide vaccines were not successful because polysaccharide vaccines are poorly immunogenic in young children, do not induce immunological memory, and do not significantly alter pharyngeal carriage (150). A conjugate meningococcal vaccine against serotype A (MenAfriVac) was developed between 2001 and 2009 and deployed in 2010. There has subsequently been a dramatic decrease in Neisseria meningitidis A disease cases in the meningitis belt, especially since 2010, in countries that have introduced the meningococcal A conjugate vaccine (10; 09; 146; 150; 07; 32; 169; 110). The vaccine was introduced at different times in different countries: it was introduced in 2010 across Burkina Faso, Mali, and Niger, whereas it was introduced from 2011 to 2016 in other countries (110). Nevertheless, since this vaccine was introduced, there has been a decrease in the number of cases in the countries that adopted the vaccine
With the reduction in the incidence of serogroup A meningococcal meningitis in the meningitis belt as a result of mass meningitis vaccination specific to that serogroup, there has been so-called “serogroup replacement” with an increase in the incidence of serogroups W, X, and C, and also an increase in pneumococcal meningitis (03; 150; 07; 62; 81; 177; 192; 212). In 2015 an epidemic of serogroup C meningitis occurred in Niger and Nigeria with around 11,000 cases and 800 deaths (09). The World Health Organization has concluded that there is a high risk of continuing expansion of serogroup C meningitis epidemics across the meningitis belt of sub-Saharan Africa (09). The ongoing wave of serogroup C meningitis in sub-Saharan Africa is caused by a unique clone genetically distant from other known serogroup C strains. Unfortunately, population immunity to serogroup C across the meningitis belt is low because the last serogroup C epidemics in the area were in the late 1970s, and few vaccination campaigns with a serogroup C-containing vaccine have been conducted (09). It is now clear that effective control of meningococcal meningitis in the African meningitis belt cannot be achieved and will require an improved surveillance system, provision of rapid antigen detection kits, and availability of an affordable vaccine that provides protection against the main serogroups causing meningitis in the region (03; 150).
In the African meningitis belt, carriers of Neisseria meningitidis are a key source of transmission (15). In this area, the duration of carriage with any Neisseria meningitidis averages 3 months (15). Meningococcal carriage in the African meningitis belt peaks at a younger age compared to Europe, with a low prevalence in infants (0.6% in the rainy season) and a broad peak at the age of 10 (1.9%) (60; 61). The odds of meningococcal carriage are significantly increased during the dry season (OR 1.5) and during outbreaks (OR 6.7) (60). Sore throat symptoms during the dry season, but not during the rainy season, were associated with a higher risk of acquisition of meningococcal carriage (61). Males and children acquire and lose carriage more frequently in urban settings within the African meningitis belt (15).
The Hajj. Outbreaks of invasive meningococcal disease have repeatedly occurred during the Hajj, the annual Islamic pilgrimage to Mecca (Makkah) in Saudi Arabia (144; 05). The latest outbreaks occurred during the Hajj pilgrimages of 2000 and 2001 and were associated with a shift from serogroup A to serogroup W135 disease (144; 116).
Coudeville and colleagues categorized countries or territories into five N meningitidis transmission clusters (63). First, countries were divided into three clusters (or zones) based on the prevalence of meningitis and infection risk labelled as high, medium, and low transmission clusters. In addition, Mecca and the Kingdom of Saudi Arabia outside of Mecca were considered separate clusters due to their strategic locations (subject to increased risk during the Hajj of meningitis transmission for the population belonging to these areas). Carriage rates varied across these clusters or zones.
Table 3. N meningitidis Carriage Rates for Different Countries or Territories as a Function of "Transmission Clusters," Determined by The Prevalence of Meningitis and Infection Risk as well as Areas Subject to An Increased Risk During the Hajj
|
Clusters |
Country of territories |
Carriage rate (%) |
|
Cluster 1: Mecca |
Mecca (Hajj city) |
4.2 [2.0, 17.8] |
|
Cluster 2: KSA outside Mecca |
Kingdom of Saudi Arabia (Hajj country) except Mecca |
1.2 [0.5, 3.2] |
|
Cluster 3: High transmission |
African meningitis belt countries (Benin, Burkina Faso, Cameroon, Central African Republic, Chad, Ivory Coast, Congo, Democratic Republic of Congo, Ethiopia, Gambia, Guinea, Ghana, Mali, Mauritania, Niger, Nigeria, Senegal, South Sudan, Sudan, Togo |
6.3 |
|
Cluster 4: Medium transmission |
South Africa, Asia (except Turkey, Malaysia, The Philippines, Indonesia, Russia, China), Arabic Non-GCC |
4.0 |
|
Cluster 5: Low transmission |
Gulf Cooperation Council countries (except KSA), Europe, Americas, Australia, Turkey, Malaysia, The Philippines, Indonesia, Russia, China |
2.0 |
|
| ||
Increased density of contacts during Hajj generates an estimated 78-fold increase in disease transmission that impacts not only pilgrims but also the local population (63). Hajj has a limited, though not negligible, impact on invasive meningococcal disease transmission and exportation in the countries of origin of the pilgrims. Quadrivalent ACWY vaccination is effective in reducing the outbreak risk during Hajj.
Prevention
|
• Meningococcal disease risk can be decreased by approximately 90% in patient household contacts by administration of antibiotics known to eradicate meningococcal carriage. | |
|
• There are no high-quality experimental trials addressing control policies for meningococcal disease and no adequate studies of chemoprophylaxis in daycare settings. Nevertheless, management guidelines support chemoprophylaxis within 24 hours for all close contacts. | |
|
• Rifampin, ceftriaxone, and ciprofloxacin are acceptable for chemoprophylaxis in adults, whereas in children, rifampin or ceftriaxone are acceptable. | |
|
• Close contacts (eg, same household, school, or daycare center) must be observed carefully for development of febrile illness. Contacts who develop a febrile illness should receive urgent medical evaluation and, if indicated, appropriate antimicrobial therapy for invasive meningococcal disease. | |
|
• In hospitalized patients, droplet precautions are recommended for the first 24 hours after initiation of effective therapy. | |
|
• The United States Centers for Disease Control and Prevention recommends routine vaccination with quadrivalent meningococcal conjugate vaccine of adolescents 11 to 18 years of age and vaccination of persons 9 months to 55 years of age who have an increased risk of invasive meningococcal disease. | |
|
• There are two types of meningococcal vaccines available in the United States: (1) meningococcal polysaccharide vaccine and (2) meningococcal conjugate vaccines. |
Meningococcal disease risk can be decreased by approximately 90% in a patient’s household contacts by administration of antibiotics known to eradicate meningococcal carriage (172). This is based on a meta-analysis of four retrospective studies and one small trial with 1249 cases of meningococcal disease and more than 4200 household contacts (172). Chemoprophylaxis significantly decreased the risk of meningococcal disease for household contacts with a risk ratio of 0.11 for those receiving chemoprophylaxis (172). The number needed to treat to prevent a single secondary household case was 218 (172). Therefore, chemoprophylaxis should be recommended for the index patient with meningococcal disease and all household contacts within 24 hours of diagnosis of the primary case. In the United States, antimicrobial chemoprophylaxis is the primary means of preventing meningococcal disease among close contacts of a patient with invasive meningococcal disease (19).
There are no high-quality experimental trials addressing control policies for meningococcal disease and no adequate studies of chemoprophylaxis in daycare settings. Nevertheless, management guidelines support chemoprophylaxis within 24 hours for all close contacts (57). Chemoprophylaxis administered more than 14 days after contact with an index case is probably of no value. Also, chemoprophylaxis does not protect against subsequent reacquisition of N meningitidis.
Table 4. Close Contacts Warranting Chemoprophylaxis for Meningococcal Disease
|
• Household contacts (including persons who ate or slept in the same dwelling as the patient during the 7 days before disease onset) | |
|
• Childcare and nursery school contacts | |
|
• Persons having contact with patient’s oral secretions during the 7 days before disease onset | |
|
-- Kissing | |
|
• Aircraft contacts for persons seated next to the patient during flights of more than 8 hours, including ground time | |
Table 5. Persons at Low Risk for Whom Chemoprophylaxis is Not Recommended
|
• Casual contact (eg, at school or work) without direct exposure to patient’s oral secretions | |
Rifampin, ceftriaxone, and ciprofloxacin are acceptable for chemoprophylaxis in adults, whereas in children rifampin or ceftriaxone are acceptable (41; 42; 57). A single 500 mg oral dose of azithromycin was also reported to be effective in eradicating nasopharyngeal carriage of N meningitidis (90; 19). In most instances, for both adults and children, the drug of choice is rifampin, which is both effective and inexpensive. For young children, rifampin can be administered with greater patient acceptance in a flavored syrup. Rifampin is not recommended for use in pregnant women. Rifampin may interfere with the efficacy of oral contraceptives, and some antiepileptic and anticoagulant medications. Rifampin may also stain the urine orange for a couple of days and may stain soft contact lenses. Ciprofloxacin is also not recommended for use in pregnant women.
Table 6. Regimens for Chemoprophylaxis of Index Cases and High-Risk Contacts
|
Drug |
Dose |
Route and duration | ||
|
Rifampin | ||||
|
1 month or less |
5 mg/kg q12 hours |
orally, 2d | ||
|
More than 1 month |
10 mg/kg q12 hours |
orally, 2d | ||
|
Adults |
600 mg q12 hours |
orally, 2d | ||
|
Ceftriaxone* | ||||
|
15 years or less |
125 mg |
intramuscularly, single dose | ||
|
More than 15 years |
250 mg |
intramuscularly, single dose | ||
|
Ciprofloxacin | ||||
|
Adults |
500 mg |
orally, single dose | ||
|
| ||||
Close contacts (eg, same household, school, or daycare center) must be observed carefully for the development of febrile illness. Contacts who develop a febrile illness should receive urgent medical evaluation and, if indicated, appropriate antimicrobial therapy for invasive meningococcal disease (57).
In hospitalized patients, droplet precautions are recommended for the first 24 hours after initiation of effective therapy (57).
Indications and contraindications for meningococcal vaccination. The United States Centers for Disease Control and Prevention recommends routine vaccination with quadrivalent meningococcal conjugate vaccine of adolescents 11 to 18 years of age and vaccination of persons 9 months to 55 years of age who have an increased risk of invasive meningococcal disease (47; 50; 42b; 52). Vaccination coverage of adolescents remains low in the United States but is improving (96; 128). Indications and contraindications for meningococcal immunization are listed below (38; 40; 41; 50; 51; 52; 57; 120; 216; 229). Travelers to the African sub-Saharan meningitis belt or the African Greater Lakes area during the dry season (December through June) or to Saudi Arabia during the Hajj should receive a meningococcal vaccine that provides coverage of all four serogroups (229).
Table 7. Indications for Immunization with Meningococcal Conjugate Vaccines
|
• Adolescents (aged 11 through 18 years) | ||
|
• Decreased resistance | ||
|
- Persons (aged 9 months to 55 years) with persistent complement component deficiency1 | ||
|
• Increased exposure risk | ||
|
- Travelers to or residents of countries (aged 9 months to 55 years) with hyperendemic or epidemic meningococcal disease 3 | ||
|
Notes: (1) C5-C9, properdin, factor H, or factor D (2) Infants with asplenia should not be vaccinated against meningococcal disease because of potential interference with pneumococcal vaccine (3) West Africa during the dry season from December to June and Saudi Arabia during the annual Hajj (4) For serogroups contained in the vaccine | ||
Table 8. Contraindications to Vaccination against Meningococcal Disease
|
• Severe (life-threatening) allergic reaction to a previous dose of MCV4 or MPSV4 vaccine. (Such individuals should not get another dose of either vaccine.) |
|
• Severe (life-threatening) allergy to any vaccine component |
|
• Moderate or severe illness at the time the shot is scheduled |
Routine immunization of children is not recommended by the Centers for Disease Control or the Committee on Infectious Disease of the American Academy of Pediatrics, in part because the infection rate is low, the immunogenic response to the vaccine is poor in young children, the immunity is relatively transient, and the quadrivalent vaccine is unlikely to be cost-effective under these circumstances (02). Parents can, nevertheless, reasonably choose to have older children receive the vaccine because the vaccine is safe and effective (161).
Barriers to vaccination. Recommendations for invasive meningococcal disease vaccination vary markedly among countries (204). Vaccination programs have targeted mainly infants and toddlers, and although they have successfully reduced the number of cases in those groups, meningococcal disease now affects more adults (204).
In the United States, there continue to be gaps in awareness of Meningococcal serogroup B disease, vaccination, and shared clinical decision-making among parents and adolescents, resulting in missed opportunities for discussing and administering Meningococcal serogroup B vaccination (102).
In the United Kingdom, France, Germany, Italy, Brazil, Argentina, Australia, and the United States, pediatric vaccination rates declined during the COVID-19 pandemic. Thirty percent of meningitidis vaccination appointments were canceled or delayed during the pandemic, and 21% of parents did not intend to reschedule them because of lockdown or stay-at-home regulations and fear of catching COVID-19 in public places (207).
In a meta-analysis of studies of predictors of meningococcal vaccine uptake among university and college students, the most common carriers of meningococcal disease, higher vaccination uptake was associated with being a first-year or undergraduate student, not being an international student, perceiving meningococcal disease as a risk, and being female (228).
Types of meningococcal vaccines. There are two types of meningococcal vaccines available in the United States: (1) meningococcal polysaccharide vaccine, and (2) meningococcal conjugate vaccines. Quadrivalent conjugate vaccines (MCV4) have immunogenicity comparable to quadrivalent polysaccharide vaccines (MPSV4) and a similar adverse reaction profile, but quadrivalent conjugate vaccines will likely provide a longer duration of protection from meningococcal disease; so, according to the Advisory Committee on Immunization Practices and the Centers for Disease Control and Prevention, conjugate vaccines (MCV4) are preferred for persons 55 years of age and younger (142; 46; 48; 179). For short-term (3 to 5 years) protection against meningococcal disease, or if quadrivalent conjugate vaccines (MCV4) are not available, the quadrivalent polysaccharide vaccine (MPSV4) is an acceptable alternative for persons aged 2 to 55 years (19; 46). The quadrivalent polysaccharide vaccine (MPSV4) continues to be recommended for persons aged older than 55 years (48). Meningococcal vaccines can be given during pregnancy. Except for children with sickle cell disease or without a working spleen, meningococcal vaccines may be given at the same time as other vaccines.
A flow chart has been developed by the U.S. Centers for Disease Control and Prevention for recommended meningococcal vaccines for persons at increased risk for meningococcal disease due to serogroups A, B, C, W, or Y and who are due for both meningococcal A, C, W, and Y vaccine and meningococcal B vaccine (56).
The quadrivalent polysaccharide vaccine. Meningococcal polysaccharide vaccines were initially developed in the 1970s (237). The immunogenicity and clinical efficacy of serogroup A and C meningococcal polysaccharide vaccines are well-established (19; 170). Estimated clinical efficacy of these vaccines is at least 85% among school-aged children and adults. Clinical efficacy has not been similarly documented for serogroup Y and W polysaccharide vaccines, but these vaccines have been demonstrated to be safe and immunogenic for persons older than 2 years.
A quadrivalent meningococcal polysaccharide vaccine effective against meningococci in groups A, C, Y, and W (Menomune) was licensed in 1981 in the United States for adults and for children 2 years of age and older. For both adults and older children, the vaccine is administered subcutaneously as a single 0.5 ml dose. Children between 3 months to 2 years of age who need the vaccine are generally given two 0.5 ml doses three months apart. Protective antibody levels are typically achieved by 7 to 10 days after vaccination. MPSV4 can be administered concurrently with other vaccines, but at different anatomic sites. Because antibody concentrations decline over several years after MPSV4 vaccination, high-risk patients should be re-immunized within 3 to 5 years; this applies to those with terminal complement component deficiencies or asplenia and travelers or residents of hyperendemic or epidemic areas.
Adverse reactions to meningococcal polysaccharide vaccines are generally mild, including most commonly injection site pain and redness or transient fever (19). Severe reactions are uncommon but can include systemic allergic reactions (eg, urticaria, wheezing, rash, or anaphylaxis) and neurologic reactions (eg, seizures or paresthesias).
In general, meningococcal polysaccharide vaccines are generally poorly immunogenic in children, often require repeated doses in children, do not produce long-lasting immunity, do not cause a sustained reduction in nasopharyngeal carriage, and do not interrupt transmission sufficiently to elicit herd immunity (237; 19; 170; 206). This is because bacterial polysaccharides, including capsular polysaccharides of N meningitidis, are T-cell-independent antigens (19). Such antigens stimulate mature B-lymphocytes but not T-lymphocytes, so the immunological response is neither long-lasting nor capable of eliciting a memory response after repeated challenge with the same antigen (19; 206). Therefore, dosing is required every 3 to 5 years.
Conjugate vaccines. Meningococcal conjugate vaccines (ie, in which meningococcal polysaccharides have been conjugated to carrier proteins) are licensed in the United States and other countries. Conjugate vaccines are immunogenic, can induce high concentrations of bactericidal antibodies, induce immunologic memory, reduce colonization, and provide herd immunity to the general population (161; 19; 89; 206; 130; 145). They are highly effective in preventing meningococcal disease for all age groups, including infants and young children, they avoid the need for revaccination, and they have been associated with minimal side effects (161; 237; 19). The benefits of conjugate vaccines compared with polysaccharide vaccines result from covalent bonding (ie, conjugation) of a bacterial polysaccharide with a protein carrier that contains T-cell epitopes, which produces a T-cell-dependent immune response. This substantially increases the primary immune response to vaccination among infants and young children and produces a strong memory response with re-exposure (19). Unlike the situation with pneumococcal vaccination, there is little evidence for the spread of virulent escape variants of N meningitides as a result of the development of conjugate vaccines (130).
A serogroup C meningococcal conjugate vaccine has been highly effective at reducing the incidence of serogroup C invasive meningococcal disease and has shown a high level of safety, with rare mild transient adverse effects (162; 213; 33; 125; 182; 04; 66). In the United Kingdom, beginning in 1999, meningococcal serogroup C vaccination with a conjugate vaccine (MenC) was introduced into the routine immunization schedule for children at 2, 3, and 4 months of age (161; 162; 213; 206). Vaccine effectiveness for children vaccinated in the routine immunization program fell to low levels after 1 year (162; 213; 33). Vaccine effectiveness, however, remained high (ie, greater than 90% after 4 years of follow-up) for older children vaccinated between the ages of 5 months and 18 years in a “catch-up” campaign (162; 213; 206). MenC provided significant herd immunity and led to a decline in disease even among unvaccinated people, due to reduced carriage among teenagers (the main reservoir for meningococcal transmission) (174; 33; 206). Overall, the serogroup C immunization program in the United Kingdom caused a noticeable decrease in the number of meningococcal cases, without simply shifting the distribution of cases to other serotypes (especially serogroup B). Similarly, from 2001 to 2005 all Canadian provinces introduced a meningococcal serogroup C conjugate vaccine into their routine infant immunization schedule (182). However, in some countries, such as Brazil, the timing of changes in invasive meningococcal disease incidence did not correspond to the dissemination of serogroup C meningococcal conjugate vaccine and suggested that other factors were responsible for much of the change in disease incidence (66). From implementation during 2001 to 2005 through 2012, this vaccine dramatically reduced the incidence of serogroup C invasive meningococcal disease in Canada through both direct and indirect effects (72; 182).
Although the optimum dose priming schedule of serogroup C meningococcal conjugate vaccine (MenC) in infants has not been established, vaccination programs with two priming doses can be reduced to a single priming dose without reducing post-boost antibody titers (168). Because of rapid waning of bactericidal antibody induced by a single conjugate vaccine dose at 12 months of age without infant priming (ie, “a toddler-only schedule”), programs using toddler-only schedules need to rely on herd protection to protect infants and young children (168).
A meningococcal serogroup C (MenC) vaccine was included in an investigational heptavalent combination vaccine that also included diphtheria, tetanus, acellular pertussis, hepatitis B, poliomyelitis, and Haemophilus influenzae type b (Hib) (210). In an open, phase II, randomized study, this heptavalent vaccine induced non-inferior MenC responses and had a similar safety profile compared with control vaccines (210).
Control of meningitis epidemics in Africa has relied on a complicated reactive vaccination strategy with polysaccharide vaccines that have not been successful in halting the recurrent epidemics (123). An affordable meningococcal A polysaccharide/tetanus toxoid conjugate vaccine (PsA-TT, MenAfriVac™) has now been developed and tested in clinical trials in Africa; these trials demonstrated the vaccine to be safe and to generate a sustained immunological response with high antibody titers (20 times those achieved with polysaccharide vaccine) (123; 206; 122; 197; 145; 68). The meningococcal A conjugate vaccine is highly effective at preventing serogroup A invasive meningococcal disease or carriage (68). No licensed vaccine is currently available against serogroup X meningococci, but a candidate conjugate vaccine against serogroup X meningococcal disease is in development (148; 235).
The World Health Organization now strongly promotes mass vaccination campaigns in individuals aged 1 to 29 years in all countries in the African meningitis belt (234). The World Health Organization recommends a 1-dose schedule, with vaccine administration by deep intramuscular injection (preferably in the anterolateral aspect of the thigh) at 9 to 18 months of age (234). MenAfriVac 5 mg should be used for routine immunization of infants and young children from 3 to 24 months of age, but MenAfriVac 10 mg should be used for catch-up and periodic campaigns from individuals who are 12 months of age and older (234). Because vaccination of pregnant women is safe, pregnant women should be included in the mass vaccination campaigns (234).
Because of the relatively high incidence of group Y disease, quadrivalent meningococcal conjugate vaccines that are effective against meningococci in groups A, C, Y, and W (MCV4) have been developed. Menveo® (MenACWY‐CRM) (Novartis) is administered as a single intramuscular dose, requires reconstitution, and is licensed for persons aged 2 to 55 years (59). Menactra™ (MenACWY‐D) (Sanofi Pasteur) is administered as a single intramuscular dose, does not require reconstitution, and is licensed for persons aged 9 months to 55 years. Protective levels of antibodies are usually achieved within 7 to 10 days of vaccination. MCV4 vaccines also elicit a T-cell-dependent immune response and are, therefore, anticipated to provide immunity for more than 8 years. MCV4 can be administered concurrently with other vaccines but at different anatomic sites (70; 87). Unfortunately, the immunogenicity of conjugate vaccines is generally poor in infants and young children, the most vulnerable group (195). In a phase 3, observer-blind, randomized controlled trial, MenACWY-CRM reduced meningococcal carriage rates among university students aged 18 to 24 years during 12 months after vaccination (175). Post-licensure safety surveillance of complications associated with routine use of quadrivalent meningococcal diphtheria toxoid conjugate vaccine (MenACWY-D) in infants and children did not identify any new safety concerns (94). Vaccine-induced serogroup replacement has not been observed in the United States after licensure of the quadrivalent meningococcal conjugate vaccine (227).
In response to an epidemic of invasive meningococcal disease due to serogroup W in the Netherlands, the meningococcal-serogroup-C-conjugated-to-tetanus-toxoid (MenC-TT) vaccine for toddlers was replaced by the MenACWY-TT vaccine in May 2018. A mass vaccination campaign targeting individuals aged 14 to 18 years was implemented in 2018 and 2019, and the quadrivalent vaccine was introduced for all individuals aged 14 years old in a national immunization program in 2020 (163). The MenACWY vaccination program was effective in preventing serogroup W invasive meningococcal disease in the target population.
Because of the risk from meningococcal disease, the Centers for Disease Control and Prevention continue to recommend routine vaccination with MCV4 for adolescents, college freshmen living in dormitories, and other high-risk populations (44; 45; 27).
Table 9. Meningococcal Conjugate Vaccine Recommendations by Risk Group*
|
Risk group |
Primary series |
Booster dose |
|
Persons aged 11 to 18 years |
One dose, preferably at age 11 or 12 years |
At age 16 years, if primary dose at age 11 to 12 years At age 16 to 18 years, if primary dose at age 13 to 15 years No booster needed if primary dose on or after age 16 years |
|
HIV-infected persons aged 11 to 18 years |
Two doses, 2 months apart |
At age 16 years, if primary dose at age 11 to 12 years At age 16 to 18 years, if primary dose at age 13 to 15 years No booster needed if primary dose on or after age 16 years |
|
Children aged 9 through 23 months at high risk for invasive meningococcal disease (except children with functional or anatomic asplenia)# |
Two doses, 3 months apart (if dose two is not received on schedule: administer a catch-up dose at the earliest opportunity) |
Initial booster 3 years after completing the primary series (if the child remains at increased risk for meningococcal disease) Continued boosters at 5-year intervals after the initial booster |
|
Persons aged 2 to 55 years with persistent complement component deficiency (eg, C5 to C9, properdin, or factor D) or functional or anatomical asplenia |
Two doses, 2 months apart |
Every 5 years At the earliest opportunity, if a 1-dose primary series is administered, then every 5 years |
|
Persons aged 2 to 55 years with prolonged increased risk for exposure† |
One dose |
Persons aged 2 to 6 years: after 3 years Persons aged 7 years or older: after 5 years if person remains at increased exposure |
|
# Children who have persistent complement component deficiencies (eg, C5-C9, properdin, factor H, or factor D), children who are traveling to or residents of countries where meningococcal disease is hyperendemic or epidemic, and children who are in a defined risk group during a community or institutional meningococcal outbreak. † Microbiologists routinely working with Neisseria meningitidis and travelers to or residents of countries where meningococcal disease is hyperendemic or epidemic. Adapted from (50; 51; 52) | ||
In general, adverse reactions to meningococcal conjugate vaccines are generally mild (124; 125), although local adverse reactions are somewhat more common than among those receiving meningococcal polysaccharide vaccines (19). Severe reactions are uncommon (estimated at 7 per 100,000) and similar in frequency to those reported with meningococcal polysaccharide vaccines (19; 124). Data suggest a small increased risk for Guillain-Barré syndrome after MCV4 vaccination, with a peak onset time from 9 to 15 days after vaccination (43; 44; 45; 46; 27). In general, persons with a history of Guillain-Barré syndrome should not be vaccinated with MCV4 (43; 45), although the language in recommendations from the Centers for Disease Control and Prevention considers a history of Guillain-Barré syndrome to be “a caution to administering MCV4” (46).
Bivalent conjugate vaccine (Serogroups C and Y). On June 14, 2012, the Food and Drug Administration approved a combination vaccine against two types of meningococcal diseases and Hib disease for infants and children 6 weeks to 18 months old. The vaccine, Menhibrix, is a tetanus toxoid conjugate vaccine that prevents disease caused by Neisseria meningitidis serogroups C and Y and Haemophilus influenzae type b. This is the first meningococcal vaccine that can be given to infants as young as 6 weeks old. Menhibrix is given as a 4-dose series, usually at 2, 4, 6, and 12 through 15 months of age, although the first dose may be given as early as 6 weeks of age and the fourth dose may be given as late as 18 months of age.
Group B meningococcal disease. Development of an effective vaccine for prevention of group B meningococcal disease had been long delayed because the serogroup B capsular polysaccharide is poorly immunogenic in humans (19; 27; 55). The serogroup B capsular polysaccharide is composed of alpha-2,8-linked polysialic acid, which is structurally identical to the posttranslational modification that occurs on neural cell adhesion molecules; therefore, it has immune tolerance (82; 176; 206).
Subsequent efforts at vaccine development focused on identifying potential outer membrane protein targets that elicit broadly protective immune responses across strains (85; 141; 206; 86; 230). In 2004, Fletcher and colleagues at Wyeth Vaccines Research identified LP2086 as a novel Neisseria meningitidis antigen with vaccine potential (85). LP2086 is a family of approximately 28-kDa lipoproteins localized to the outer surface of Neisseria meningitidis (85; 141). More than 600 LP2086 amino acid sequence variants have been identified that can be classified into two subfamilies, subfamily A and B (85; 166; 155; 118). Because LP2086 selectively binds to human factor H, the key regulator of the alternative complement pathway, LP2086 is also known as factor H binding protein (fHbp) (186). Binding of factor H to fHbp enables Neisseria meningitidis to evade killing by the innate immune system (187). A further designation for LP2086 is GNA1870, indicating a specific genome-derived antigen (167).
Preclinical studies demonstrated that LP2086 induces cross-reactive bactericidal antibodies against various Neisseria meningitidis strains (85; 166). The bactericidal antibody response correlates with the amount of LP2086 expressed on the bacterial surface (186). Preliminary work at Wyeth Vaccines Research showed that a formulation containing both subfamilies of LP2086 could potentially provide broad protection against a majority of Neisseria meningitidis strains, and later studies confirmed the broad coverage potential of a bivalent recombinant LP2086 vaccine (166; 113; 134). LP2086 is expressed in vivo during both carriage and invasive disease at levels high enough to elicit a robust antibody response (06).
Two recombinant protein-based serogroup B vaccines have been developed and licensed in the United States under an accelerated approval process, both of which incorporate LP2086: bivalent rLP2086 (MenB-FHbp; Trumenba®) and 4CMenB (MenB-4 C; Bexsero®) (133).
Bivalent rLP2086 vaccine comprises two fHbp variants, where each antigen represents one of the two known LP2086 subfamilies recombinantly expressed in Escherichia coli. In young adults, bivalent rLP2086 vaccine is well-tolerated and induces potent bactericidal antibodies against diverse serogroup B strains (178; 190; 129). Bivalent rLP2086 vaccine is also well-tolerated and immunogenic in healthy children and adolescents (159). Because of high rates of fever in phase I and II trials in infants, further investigations in this age group are not being pursued (135; 25). Bivalent rLP2086 received accelerated approval from the U.S. Food and Drug Administration in October 2014. The vaccine is licensed to prevent meningococcal meningitis disease caused by N meningitidis serogroup B in individuals 10 to 25 years of age.
4CMenB is a multicomponent meningococcal serogroup B vaccine that has been licensed for use in Europe (January 2013), Australia (August 2013), Canada (December 2013), and the United States (January 2015). The vaccine contains four main immunogenic components: three recombinant proteins combined with outer membrane vesicles derived from a specific meningococcal strain (NZ98/254) (34; 08). Before licensure in the United States, the Food and Drug Administration allowed the use of the vaccine under an Investigational New Drug application to help control a specific outbreak of serogroup B meningococcal disease at Princeton University in 2013–2014 (140; 16). In that outbreak, no serogroup B meningococcal disease cases occurred in persons who received at least one dose of the 4CMenB vaccine, suggesting that 4CMenB may have protected vaccinated individuals from disease even though carriage of serogroup B Neisseria meningitidis among vaccinated persons was not eliminated (140). In a phase 3, observer-blind, randomized controlled trial conducted at 10 sites in England, 4CMenB reduced meningococcal carriage rates among university students aged 18 to 24 years during 12 months after vaccination (175). The breadth of protection the vaccine may induce against the diverse pathogenic serogroup B strains is still uncertain (08). Nevertheless, modeling has suggested an optimal vaccination strategy of routine vaccination at ages 2 months, 3 months, 4 months, 12 months, and 14 years combined with a 5-year catch-up program in toddlers aged 12 to 24 months and adolescents aged 15 to 18 years (108). Although 4CMenB may have a protective role in clusters and outbreaks, early protection offered after a single dose of Bexsero® is likely to be low, particularly in young children who are at higher risk of secondary infection (121). Indeed, for infants, the percent reduction in cases at 1-year follow-up is only 50%, but this rises to 90% to 94% at 3 to 4 years, respectively (133). The safety profile of 4CMenB administered in real-world settings is consistent with pre-licensure clinical trial data (133). An Italian study identified 23 cases of serious adverse events among 4773 immunizations of infants from 2020 to 2023, 78% of which were deemed to have a consistent causal association with the administration of 4CMenB. Three infants were hospitalized following vaccination, but no deaths or permanent or severe impairment were reported (198).
Differential diagnosis
Confusing conditions
In neonates, bacterial meningitis is typically caused by organisms acquired from the maternal genital tract and gastrointestinal tract around the time of birth (eg, Streptococcus group B, Escherichia coli, Streptococcus pneumoniae, and Listeria monocytogenes), whereas in older children and young people, bacterial meningitis is usually caused by organisms that can colonize the upper respiratory tract and cause invasive disease in susceptible people (eg, N meningitides, Streptococcus pneumoniae, or Haemophilus influenzae type b). N meningitidis and Streptococcus pneumoniae are the most commonly identified organisms in cases of meningitis in children 1 to 23 months of age (185). N meningitidis causes most cases of meningitis in children between ages 2 and 18 years. The highest incidence of meningococcal disease occurs in children under age 2 years, with further peaks in incidence occurring in adolescence and early adulthood.
An acute fulminating presentation with fever, petechial or purpuric rash, prostration, and hypotension is strong evidence of meningococcal disease. Often, however, meningococcal meningitis cannot be distinguished clinically from other causes of bacterial meningitis. Many cases of meningococcal meningitis present atypically without the classic triad of fever, neck stiffness, and change in mental status (220). A high index of suspicion is needed, particularly in infants and small children.
Diagnostic workup
|
• Signs indicating a high risk of meningococcal disease in children and young people with a petechial rash include changes in the rash in which either petechiae start to spread or the rash becomes purpuric, development of signs of bacterial meningitis or of meningococcal septicemia, or appearing seriously ill. According to the United Kingdom's National Institute for Health and Clinical Excellence (NICE) Guidelines, such individuals should receive intravenous ceftriaxone immediately without waiting for other diagnostic studies. | |
|
• Lumbar puncture is indicated for suspected meningitis or suspected meningococcal disease unless contraindications are present. | |
|
• Bacterial antigen detection tests, gram stains, and culture are generally considered the most useful diagnostic tests. | |
|
• Polymerase-chain reaction analysis can detect serogroup-specific Neisseria meningitidis DNA with high sensitivity and specificity even with dead organisms. |
Signs indicating a high risk of meningococcal disease in children and young people with a petechial rash include changes in the rash in which either petechiae start to spread or the rash becomes purpuric, development of signs of bacterial meningitis or of meningococcal septicemia, or appearing seriously ill (ie, to a healthcare professional) (225). According to the United Kingdom's National Institute for Health and Clinical Excellence (NICE) Guidelines, such individuals should receive intravenous ceftriaxone immediately without waiting for other diagnostic studies (225).
If a child or young person has an unexplained petechial rash and fever (or history of fever) without high-risk clinical manifestations, the NICE Guidelines recommend the following studies: complete blood count, C reactive protein, coagulation screen, blood culture, whole blood polymerase chain reaction for N meningitidis, blood glucose, and arterial blood gas (225). Although a normal C reactive protein concentration and normal white blood cell count make meningococcal disease less likely, these measures may be normal or low even in severe meningococcal disease.
Lumbar puncture is indicated for suspected meningitis or suspected meningococcal disease unless contraindications are present (225). N meningitidis diplococci are typically evident on Gram stain of cerebrospinal fluid, along with a profusion of polymorphonuclear leukocytes. The CSF is characterized by a markedly elevated white blood cell count (> 500 cells/ml), with predominant neutrophils and a markedly elevated protein (> 100 mg/dl or > 1 g/l), indicating severe blood-CSF barrier disruption.
According to the NICE Guidelines, contraindications to lumber puncture in children and young people include the presence of signs of increased intracranial pressure (ie, a reduced or fluctuating level of consciousness with a score of less than 9 or a drop of at least 3 points on the Glasgow Coma Scale; relative bradycardia and hypertension; focal neurologic signs; abnormal posture or posturing; unequal, dilated, or poorly responsive pupils; papilledema; and abnormal "doll's eye" movements), shock, extensive or spreading purport, not yet stabilized from recent convulsions, coagulopathy (abnormal coagulation results if obtained), platelet count below 100 x 10(9)/L, local skin infection at lumbar puncture site, and respiratory insufficiency (225).
Bacterial antigen detection tests, gram stains, and culture are generally considered the most useful diagnostic tests. Bacterial antigen detection tests (eg, latex agglutination tests) in CSF are useful for rapid diagnosis. Rapid antigen tests from urine or serum samples are unreliable (39; 57). Gram stains of normally sterile body fluids can help establish a presumptive diagnosis of meningococcal disease (57). Cultures of blood and cerebrospinal fluid are indicated in all patients with suspected invasive meningococcal disease, and additional cultures from petechial scrapings, sputum, and other normally sterile body fluids can also sometimes be helpful (57).
Polymerase-chain reaction analysis can detect serogroup-specific Neisseria meningitidis DNA with high sensitivity and specificity even with dead organisms (30; 152). PCR can confirm the diagnosis, even when the number of bacteria is below the threshold for successful culturing, or after antibiotic administration (30). The NICE Guidelines recommend whole blood real-time PCR testing for N meningitidis to confirm a diagnosis of meningococcal disease (225).
Skin biopsy with conventional culture and meningococcal PCR has a sensitivity of 88% and should be considered in case of suspected meningococcal purpura fulminans even after initiation of antimicrobial treatment (58).
A probable case of meningococcal disease can be established with a positive antigen test in CSF or clinical purpura fulminans in the absence of a positive blood culture (39; 57). Polysaccharide can be demonstrated in cerebrospinal fluid by latex agglutination or immunohistochemistry, and DNA can be demonstrated by PCR (19). False-negative antigen test results are common, especially with serogroup B disease (181).
A presumptive case of meningococcal disease can be established by demonstration of gram-negative diplococci in a normally sterile body fluid, such as cerebrospinal fluid, an aspirate from a petechial or purpuric lesion, buffy coat smear of blood, synovial fluid, etc. (57).
A confirmed case of meningococcal disease is one with compatible clinical features and laboratory confirmation (39). Laboratory criteria for diagnosis of meningococcal disease are isolation of Neisseria meningitidis from a normally sterile site, such as the blood or cerebrospinal fluid (or less commonly from a petechial or purpuric lesion, synovial fluid, pericardial fluid, or pleural fluid) (39; 57).
Management
|
• Because of the risks of severe morbidity and death, appropriate antibiotic therapy should be rapidly initiated in patients suspected of having meningococcal disease. | |
|
• Before confirmation of meningococcal disease as the cause of the illness, empiric antibiotic coverage should be directed at the most likely pathogens based on epidemiologic considerations (eg, age, geographic location, etc.) and the known prevalence of antibiotic resistance for these organisms. | |
|
• No investigations should delay initiating antibiotic therapy once the diagnosis of meningococcal meningitis is suspected. | |
|
• According to the NICE Guidelines, children who have suspected bacterial meningitis or meningococcal disease should be immediately treated with intravenous ceftriaxone, with the addition of amoxicillin or ampicillin for children younger than 3 months. | |
|
• Recommendations for initial empiric antimicrobial therapy in adults with community-acquired bacterial meningitis are vancomycin plus a third-generation cephalosporin (eg, cefotaxime or ceftriaxone) for those aged 16 to 50 years and vancomycin plus a third-generation cephalosporin plus ampicillin for those older than 50 years, or for those with alcoholism or altered immune status. Generally, combination therapy should be continued until in vitro susceptibility testing results are available. | |
|
• Once in vitro susceptibility testing results are available, 5 to 7 days of appropriate antimicrobial therapy are usually adequate to treat invasive meningococcal disease. | |
|
• Systemic antibiotic therapy with agents other than ceftriaxone or other third-generation cephalosporins may not reliably eradicate nasopharyngeal carriage of N meningitidis. | |
|
• Corticosteroid therapy has no demonstrated efficacy for meningococcal disease. | |
|
• Patients commonly need additional therapies for seizures and hemodynamic instability, both of which occur in up to 20% of patients on presentation. | |
|
• Droplet precautions should be instituted until 24 hours after initiation of antibiotic therapy. | |
|
• In persons with bacterial meningitis, fluids should not be restricted unless there is evidence of increased intracranial pressure or increased antidiuretic hormone secretion. | |
|
• Patients should be monitored closely for evidence of deterioration, using frequent assessment of pulse, blood pressure, respiration, oxygen saturation, and Glasgow Coma Scale score. | |
|
• As part of the long-term management of children and young people with severe or profound deafness due to meningococcal meningitis, assessment for cochlear implantation should be offered as soon as possible once the patient can undergo testing. |
Because of the risks of severe morbidity and death, appropriate antibiotic therapy should be rapidly initiated in patients suspected of having meningococcal disease. Before confirmation of meningococcal disease as the cause of the illness, empiric antibiotic coverage should be directed at the most likely pathogens based on epidemiologic considerations (eg, age, geographic location, etc.) and the known prevalence of antibiotic resistance for these organisms. No investigations should delay initiating antibiotic therapy once the diagnosis of meningococcal meningitis is suspected (24). Unfortunately, antibiotic therapy is often delayed by waiting for neuroimaging and then lumbar puncture; in a Dutch study, antibiotics were not initiated before computed tomography in 85% of patients who underwent imaging before lumbar puncture (100). According to a Cochrane review, there is no reliable evidence concerning the use of pre-admission antibiotics for suspected cases of non-severe meningococcal disease, although evidence of moderate quality from one randomized controlled trial indicated that single intramuscular injections of ceftriaxone and long-acting chloramphenicol were equally effective in reducing serious outcomes (200).
According to the NICE Guidelines, children and young people with an unexplained petechial rash and fever (or a history of fever) but without high-risk clinical manifestations should be treated immediately with intravenous ceftriaxone if a C reactive protein level or white blood cell count (especially neutrophil count) is raised because either of these indicates an increased risk of meningococcal disease (225).
According to the NICE Guidelines, children who have suspected bacterial meningitis or meningococcal disease should be immediately treated with intravenous ceftriaxone, with the addition of amoxicillin or ampicillin for children younger than 3 months (225). Vancomycin should be added for those who have recently traveled outside the country or had prolonged or multiple antibiotic exposures (225). Cefotaxime should be substituted for ceftriaxone if there are calcium-containing infusions (225).
Recommendations for initial empiric antimicrobial therapy in adults with community-acquired bacterial meningitis are vancomycin plus a third-generation cephalosporin (eg, cefotaxime or ceftriaxone) for those aged 16 to 50 years and vancomycin plus a third-generation cephalosporin plus ampicillin for those older than 50 years, or for those with alcoholism or altered immune status (221). Generally, combination therapy should be continued until in vitro susceptibility testing results are available.
Once in vitro susceptibility testing results are available, 5 to 7 days of appropriate antimicrobial therapy are usually adequate to treat invasive meningococcal disease (173; 57). Antibiotic resistance is relatively uncommon in N meningitidis isolates (103). Penicillin is the drug of choice. Generally, high-dose intravenous penicillin G should be administered every 4 to 6 hours for patients with invasive meningococcal disease (57). Acceptable alternatives to penicillin G are ampicillin, cefotaxime, and ceftriaxone (173; 57). Most reported strains are moderately susceptible to high-dose penicillin G, cefotaxime, and ceftriaxone (173; 57). Other effective regimens include 3 days of intravenous benzylpenicillin (26). Chloramphenicol is indicated for patients with anaphylactic allergic reactions to penicillin (57). Chloramphenicol has also been used routinely in underdeveloped countries, but single-dose ceftriaxone is an efficacious, easy-to-use, and low-cost alternative (158). Whereas most isolates of meningococcus remain penicillin-susceptible, fluoroquinolone resistance has now been documented in the U.S. (27). Because of high rates of penicillin resistance in Spain, Italy, and parts of Africa, other agents (eg, cefotaxime, ceftriaxone, or chloramphenicol) are recommended for travelers returning from these areas (57). For patients with inadequate responses to initial therapy, bacterial isolates should be tested, and therapy should be changed to a third-generation cephalosporin if the isolate is resistant to penicillin (173).
From 2010 to 2019, 126 of 4122 invasive meningococcal disease isolates (2.9%) in England, Wales, and Northern Ireland exhibited antibiotic resistance: penicillin (n=113), ciprofloxacin (n=5), rifampicin (n=2), and cefotaxime (n=1) (231).
Systemic antibiotic therapy with agents other than ceftriaxone or other third-generation cephalosporins may not reliably eradicate nasopharyngeal carriage of N meningitidis (19). If other agents have been used for treating invasive meningococcal disease, the patient should receive chemoprophylactic antibiotics to eradicate nasopharyngeal carriage before hospital discharge (19).
Although corticosteroids may decrease the risk of hearing loss in patients with meningitis caused by other organisms, corticosteroid therapy has no demonstrated efficacy for meningococcal disease (181; 93; 218; 139; 151). However, in a systematic review for the Cochrane Collaborative, corticosteroids showed a non-significant favorable trend in mortality from meningococcal meningitis, and the lack of demonstrated benefit has been hypothesized to be due to limited power to detect a benefit rather than to no benefit (139). In any case, there is no evidence of a detrimental effect, and, in particular, dexamethasone does not appear to increase the risk of deafness or death (99). Low-dose corticosteroids have been recommended in patients with meningococcal disease and refractory shock (24). For children aged 3 months or older and young people with suspected or confirmed bacterial meningitis (including that due to N meningitidis), the NICE Guidelines recommend giving dexamethasone (0.15 mg/kg to a maximum dose of 10 mg, four times daily for 4 days) as soon as possible if lumbar puncture shows frankly purulent cerebrospinal fluid, CSF white blood cell count greater than 1000/μl, raised CSF white blood cell count with protein concentration greater than 1 g/l, or bacteria on Gram stain (225). Corticosteroids should not be used in children younger than 3 months who have suspected or confirmed bacterial meningitis (225).
Patients commonly need additional therapies for seizures and hemodynamic instability, both of which occur in up to 20% of patients on presentation (35).
Droplet precautions should be instituted until 24 hours after initiation of antibiotic therapy (57).
In persons with bacterial meningitis, fluids should not be restricted unless there is evidence of increased intracranial pressure or increased secretion of antidiuretic hormone (225). Shock should be treated with an immediate parenteral bolus of sodium chloride 0.9%. In children and young people, NICE Guidelines recommend intravenous or intraosseous sodium chloride 0.9% 20 ml/kg over 5 to 10 minutes, followed if necessary by an immediate second bolus of 20 ml/kg of intravenous or intraosseous sodium chloride 0.9% or human albumin 4.5% solution over 5 to 10 minutes (225). If the signs of shock still persist after the first 40 ml/kg, a third bolus of 20 ml/kg of intravenous or intraosseous sodium chloride 0.9% or human albumin 4.5% solution should be given over 5 to 10 minutes, in conjunction with urgent tracheal intubation and mechanical ventilation and treatment with vasoactive drugs (225). Additional fluid boluses may be required because some children and young people may require large volumes of fluid over a short period to restore their circulating volume.
Patients should be monitored closely for evidence of deterioration, using frequent assessment of pulse, blood pressure, respiration, oxygen saturation, and Glasgow Coma Scale score (225).
As part of the long-term management of children and young people with severe or profound deafness due to meningococcal meningitis, assessment for cochlear implantation should be offered as soon as possible once the patient can undergo testing (225).
Media
References
- 01
- Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Control and prevention of serogroup C meningococcal disease: evaluation and management of suspected outbreaks: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1997;46(RR-5):13-21. PMID 9048847
- 02
- Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Report from the Advisory Committee on Immunization Practices (ACIP): decision not to recommend routine vaccination of all children aged 2-10 years with quadrivalent meningococcal conjugate vaccine (MCV4). MMWR Morb Mortal Wkly Rep 2008;57(17):462-5. PMID 18451758
- 03
- Agier L, Martiny N, Thiongane O, et al. Towards understanding the epidemiology of Neisseria meningitidis in the African meningitis belt: a multi-disciplinary overview. Int J Infect Dis 2017;54:103-12. PMID 27826113
- 04
- Ajibola O, Omoleke SA, Omisakin OA. Current status of cerebrospinal meningitis and impact of the 2015 meningococcal C vaccination in Kebbi, Northwest Nigeria. Vaccine 2018;36(11):1423-8. PMID 29426659
- 05
- Al-Abri SS, Abuhasan MY, Albayat SSA, et al. Meningococcal disease in the Middle East: a report from the Global Meningococcal Initiative. J Infect 2024;88(2):71-6. PMID 37866792
- 06
- Ala'aldeen DA, Flint M, Oldfield NJ, et al. Human antibody responses to the meningococcal factor H binding protein (LP2086) during invasive disease, colonization and carriage. Vaccine 2010;28(48):7667-75. PMID 20875489
- 07
- Alderson MR, LaForce FM, Sobanjo-Ter Meulen A, Hwang A, Preziosi MP, Klugman KP. Eliminating meningococcal epidemics from the African meningitis belt: the case for advanced prevention and control using next-generation meningococcal conjugate vaccines. J Infect Dis 2019;220(Supplement_4):S274-8. PMID 31671447
- 08
- Andrews SM, Pollard AJ. A vaccine against serogroup B Neisseria meningitidis: dealing with uncertainty. Lancet Infect Dis 2014;14(5):426-34. PMID 24679664
- 09
- Anonymous. Preparedness for outbreaks of meningococcal meningitis due to Neisseria meningitidis serogroup C in Africa: recommendations from a WHO expert consultation. Wkly Epidemiol Rec 2015;90(47):633-6. PMID 26591025
- 10
- Anonymous. Meningococcal disease control in countries of the African meningitis belt, 2013. Wkly Epidemiol Rec 2014;89(20):206-14. PMID 24864346
- 11
- Artenstein AW, LaForce FM. Critical episodes in the understanding and control of epidemic meningococcal meningitis. Vaccine 2012;30(31):4701-7. PMID 22525794
- 12
- Arteta-Acosta C, Villena Martínez R, Santolaya de Pablo ME. Sequelae at hospital discharge in 61 children with invasive meningococcal disease, Chile, 2009-2019. Pediatr Infect Dis J 2022;41(8):607-13. PMID 25421054
- 13
- Asturias EJ, Bai X, Bettinger JA, et al. Meningococcal disease in North America: updates from the Global Meningococcal Initiative. J Infect 2022;85(6):611-22. PMID 36273639
- 14
- Bai X, Borrow R, Bukovski S, et al. Prevention and control of meningococcal disease: updates from the Global Meningococcal Initiative in Eastern Europe. J Infect 2019;79(6):528-41. PMID 31682877
- 15
- Basta NE, Berthe A, Keita M, et al. Meningococcal carriage within households in the African meningitis belt: a longitudinal pilot study. J Infect 2018;76(2):140-8. PMID 29197599
- 16
- Basta NE, Mahmoud AA, Wolfson J, et al. Immunogenicity of a meningococcal B vaccine during a university outbreak. N Engl J Med 2016;375(3):220-8. PMID 27468058
- 17
- Bernard SC, Simpson N, Join-Lambert O, et al. Pathogenic Neisseria meningitidis utilizes CD147 for vascular colonization. Nat Med 2014;20(7):725-31. PMID 24880614
- 18
- Bijlsma MW, Bekker V, Brouwer MC, Spanjaard L, van de Beek D, van der Ende A. Epidemiology of invasive meningococcal disease in the Netherlands, 1960-2012: an analysis of national surveillance data. Lancet Infect Dis 2014;14(9):805-12. PMID 25104306
- 19
- Bilukha OO, Rosenstein N, National Center for Infectious Diseases, Centers for Disease Control and Prevention. Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2005;54(RR-7):1-21. PMID 15917737
- 20
- Blain AE, Reese HE, Marjuki H, Topaz N, Mbaeyi S, McNamara LA. Serogroup A, C, W, and Y meningococcal disease in persons previously vaccinated with a serogroup ACWY meningococcal vaccine - United States, 2014-2018. Vaccine 2021;39(52):7541-4. PMID 34802785
- 21
- Boisier P, Micolas P, Djibo S, et al. Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in Niger. Clin Infect Dis 2007;44:657-63. PMID 17278055
- 22
- Boras A, Jeren T, Sacchi CT, et al. Establishment of an active laboratory-based surveillance for bacterial meningitis in Croatia and molecular characterization of Neisseria meningitidis isolates causing meningococcal disease that were collected in the year 2000, the first year of activity. J Clin Microbiol 2004;42:1803-6. PMID 15071056
- 23
- Borrow R, Findlow J. The important lessons lurking in the history of meningococcal epidemiology. Expert Rev Vaccines 2024;23(1):445-62. PMID 38517733
- 24
- Branco RG, Tasker RC. Meningococcal meningitis. Curr Treat Options Neurol 2010;12(5):464-74. PMID 20842601
- 25
- Brendish NJ, Read RC. Neisseria meningitidis serogroup B bivalent factor H binding protein vaccine. Expert Rev Vaccines 2015;14(4):493-503. PMID 25703792
- 26
- Briggs S, Ellis-Pegler R, Roberts S, Thomas M, Woodhouse A. Short course intravenous benzylpenicillin treatment of adults with meningococcal disease. Intern Med J 2004;34:383-7. PMID 15271171
- 27
- Brigham KS, Sandora TJ. Neisseria meningitidis: epidemiology, treatment and prevention in adolescents. Curr Opin Pediatr 2009;21(4):437-43. PMID 19421058
- 28
- Broutin H, Philippon S, Constantin de Magny G, Courel MF, Sultan B, Guégan JF. Comparative study of meningitis dynamics across nine African countries: a global perspective. Int J Health Geogr 2007;6:29. PMID 17623084
- 29
- Brusletto BS, Hellerud BC, Øvstebø R, Brandtzaeg P. Neisseria meningitidis accumulate in large organs during meningococcal sepsis. Front Cell Infect Microbiol 2023;13:1298360. PMID 38089821
- 30
- Bryant PA, Li HY, Zaia A, Griffith J, Hogg G, Curtis N, Carapetis JR. Prospective study of a real-time PCR that is highly sensitive, specific, and clinically useful for diagnosis of meningococcal disease in children. J Clin Microbiol 2004;42:2919-25. PMID 15243039
- 31
- Brynildsrud OB, Eldholm V, Bohlin J, Uadiale K, Obaro S, Caugant DA. Acquisition of virulence genes by a carrier strain gave rise to the ongoing epidemics of meningococcal disease in West Africa. Proc Natl Acad Sci U S A 2018;115(21):5510-15. PMID 29735685
- 32
- Bwaka A, Bita A, Lingani C, et al. Status of the rollout of the meningococcal serogroup a conjugate vaccine in African meningitis belt countries in 2018. J Infect Dis 2019;220(Supplement_4):S140-7. PMID 31671448
- 33
- Campbell H, Andrews N, Borrow R, Trotter C, Miller E. Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity. Clin Vaccine Immunol 2010;17(5):840-7. PMID 20219881
- 34
- Carter NJ. Multicomponent meningococcal serogroup B vaccine (4CMenB; Bexsero(®)): a review of its use in primary and booster vaccination. BioDrugs 2013;27(3):263-74. PMID 23575646
- 35
- Casella EB, Cypel S, Osmo AA, et al. Sequelae from meningococcal meningitis in children: a critical analysis of dexamethasone therapy. Arq Neuropsiquitr 2004;62:421-8. PMID 15273838
- 36
- Centers for Disease Control and Prevention. Serogroup B meningococcal disease--Oregon, 1994. MMWR Morb Mortal Wkly Rep 1995;44(7):121-4. PMID 7845348
- 37
- Centers for Disease Control and Prevention. Serogroup Y meningococcal disease--Illinois, Connecticut, and selected areas, United States, 1989-1996. MMWR Morb Mortal Wkly Rep 1996;45(46):1010-3. PMID 8965799
- 38
- Centers for Disease Control and Prevention. Control and prevention of serogroup C meningococcal disease: evaluation and management of suspected outbreaks: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1997a;46(RR-5):13-21. PMID 9048847
- 39
- Centers for Disease Control and Prevention. Case definitions for infectious conditions under public health surveillance. Centers for Disease Control and Prevention. MMWR Recomm Rep 1997b;46(RR-10):1-55. PMID 9148133
- 40
- Centers for Disease Control and Prevention. Meningococcal disease--New England, 1993-1998. MMWR Morb Mortal Wkly Rep 1999;48(29):629-33. PMID 10458536
- 41
- Centers for Disease Control and Prevention. Meningococcal disease and college students. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2000;49(RR-7):13-20. PMID 10902835
- 42
- Centers for Disease Control and Prevention. Exposure to patients with meningococcal disease on aircraft--United States, 1999-2001. MMWR Morb Mortal Wkly Rep 2001;50(23):485-9. PMID 11428727
- 43
- Centers for Disease Control and Prevention. Guillain-Barré syndrome among recipients of Menactra meningococcal conjugate vaccine – United States, June-July 2005. MMWR Morb Mortal Wkly Rep 2005;54(40):1023-5. PMID 16224452
- 44
- Centers for Disease Control and Prevention. Update: Guillain-Barré syndrome among recipients of Menactra meningococcal conjugate vaccine – United States, October 2005-February 2006. MMWR Morb Mortal Wkly Rep 2006a;55(13):364-6. PMID 16601664
- 45
- Centers for Disease Control and Prevention. Update: Guillain-Barré syndrome among recipients of Menactra meningococcal conjugate vaccine – United States, June 2005-September 2006. MMWR Morb Mortal Wkly Rep 2006b;55(41):1120-4. PMID 17060898
- 46
- Centers for Disease Control and Prevention. Recommendation from the Advisory Committee on Immunization Practices (ACIP) for use of quadrivalent meningococcal conjugate vaccine (MCV4) in children aged 2-10 years at increased risk for invasive meningococcal disease. MMWR Morb Mortal Wkly Rep 2007;56:1265-6.
- 47
- Centers for Disease Control and Prevention. Updated recommendation from the Advisory Committee on Immunization Practices (ACIP) for revaccination of persons at prolonged increased risk for meningococcal disease. MMWR Morb Mortal Wkly Rep 2009;58(37):1042-3. PMID 19779400
- 48
- Centers for Disease Control and Prevention. Licensure of a meningococcal conjugate vaccine (Menveo) and guidance for use - Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep 2010a;59(9):273. PMID 20224545
- 49
- Centers for Disease Control and Prevention. Occupational transmission of Neisseria meningitidis --- California, 2009. MMWR Morb Mortal Wkly Rep 2010b;59(45):1480-3. PMID 21085089
- 50
- Centers for Disease Control and Prevention. Updated recommendations for use of meningococcal conjugate vaccines --- Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep 2011a;60(3):72-6. PMID 21270745
- 51
- Centers for Disease Control and Prevention. Licensure of a meningococcal conjugate vaccine for children aged 2 through 10 years and updated booster dose guidance for adolescents and other persons at increased risk for meningococcal disease--Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 2011b;60(30):1018-9. PMID 21814165
- 52
- Centers for Disease Control and Prevention. Recommendation of the Advisory Committee on Immunization Practices (ACIP) for use of quadrivalent meningococcal conjugate vaccine (MenACWY-D) among children aged 9 through 23 months at increased risk for invasive meningococcal disease. MMWR Morb Mortal Wkly Rep 2011c;60(40):1391-2. PMID 21993344
- 53
- Charles-Orszag A, Tsai FC, Bonazzi D, et al. Adhesion to nanofibers drives cell membrane remodeling through one-dimensional wetting. Nat Commun 2018;9(1):4450. PMID 30361638
- 54
- Christensen H, May M, Bowen L, Hickman M, Trotter CL. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis 2010;10(12):853-61. PMID 21075057
- 55
- Cohn AC, MacNeil JR, Harrison LH, et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin Infect Dis 2010;50(2):184-91. PMID 20001736
- 56
- Collins JP, Crowe SJ, Ortega-Sanchez IR, et al. Use of the Pfizer pentavalent meningococcal vaccine among persons aged ≥10 years: recommendations of the Advisory Committee on Immunization Practices - United States, 2023. MMWR Morb Mortal Wkly Rep 2024;73(15):345-50. PMID 38635488
- 57
- Committee on Infectious Disease, American Academy of Pediatrics. Meningococcal infections. In: Pickering LK, editor. Red Book: Report of the Committee on Infectious Disease. 25th ed. Elk Grove Village, IL: American Academy of Pediatrics, 2000:396-401.
- 58
- Contou D, Béduneau G, Rabault C, et al. Skin biopsy in adult patients with meningococcal purpura fulminans: a multicenter retrospective cohort study. Crit Care 2023;27(1):166. PMID 37122034
- 59
- Cooper B, DeTora L, Stoddard J. Menveo®: a novel quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135 and Y. Expert Rev Vaccines 2011;10(1):21-33. PMID 21162617
- 60
- Cooper LV, Kristiansen PA, Christensen H, Karachaliou A, Trotter CL. Meningococcal carriage by age in the African meningitis belt: a systematic review and meta-analysis. Epidemiol Infect 2019b;147:e228. PMID 31364554
- 61
- Cooper LV, Robson A, Trotter CL, et al. Risk factors for acquisition of meningococcal carriage in the African meningitis belt. Trop Med Int Health 2019c;24(4):392-400. PMID 30729627
- 62
- Cooper LV, Ronveaux O, Fernandez K, et al. Spatiotemporal analysis of serogroup C meningococcal meningitis spread in Niger and Nigeria and implications for epidemic response. J Infect Dis 2019a;220(Supplement_4):S244-52. PMID 31671446
- 63
- Coudeville L, Amiche A, Rahman A, et al. Disease transmission and mass gatherings: a case study on meningococcal infection during Hajj. BMC Infect Dis 2022;22(1):275. PMID 35317742
- 64
- Coureuil M, Join-Lambert O, Lécuyer H, Bourdoulous S, Marullo S, Nassif X. Pathogenesis of meningococcemia. Cold Spring Harb Perspect Med 2013;3(6) pii: a012393. PMID 23732856
- 65
- Coureuil M, Lécuyer H, Scott MG, et al. Meningococcus Hijacks a β2-adrenoceptor/β-Arrestin pathway to cross brain microvasculature endothelium. Cell 2010;143(7):1149-60. PMID 21183077
- 66
- Cruz MC, Camargos P, Nascimento-Carvalho CM. Impact of meningococcal C conjugate vaccine on incidence of invasive meningococcal disease in an 18-year time series in Brazil and in distinct Brazilian regions. Trop Med Int Health 2022;27(3):280-9. PMID 34997999
- 67
- Darbà J, Kaskens L, Hark M, Wright C. Costs of surviving meningococcal disease in Spain: evaluation for two cases of severe meningitis and septicaemia. Vaccine 2014;32(39):5006-12. PMID 25045813
- 68
- Daugla DM, Gami JP, Gamougam K, et al. Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study [corrected]. Lancet 2014;383(9911):40-7. PMID 24035220
- 69
- Decosas J, Koama JB. Chronicle of an outbreak foretold: meningococcal meningitis W135 in Burkina Faso. Lancet Infect Dis 2002;2:763-5. PMID 12467693
- 70
- Deeks ED. Meningococcal quadrivalent (serogroups A, C, w135, and y) conjugate vaccine (Menveo): in adolescents and adults. BioDrugs 2010;24(5):287-97. PMID 20795751
- 71
- Delbaz A, Chen M, Jen FE, et al. Neisseria meningitidis induces pathology-associated cellular and molecular changes in trigeminal Schwann cells. Infect Immun 2020;88(4):e00955-19. PMID 31964742
- 72
- de Wals P, Deceuninck G, Boulianne N, De Serres G. Effectiveness of a mass immunization campaign using serogroup C meningococcal conjugate vaccine. JAMA 2004;292:2491-4. PMID 15562128
- 73
- Doyle TJ, Gumke M, Stanek D, et al. Concurrent outbreaks of hepatitis A, invasive meningococcal disease, and mpox, Florida, USA, 2021-2022. Emerg Infect Dis 2024;30(4):633-43. PMID 38526187
- 74
- Duarte MC, Amorim MR, Cuevas LE, Cabral-Filho JE, Correia JB. Risk factors for death from meningococcal infection in Recife, Brazil. J Trop Pediatr 2005;51:227-31. PMID 16000346
- 75
- Dubey H, Oster P, Fazeli MS, et al. Risk factors for contracting invasive meningococcal disease and related mortality: a systematic literature review and meta-analysis. Int J Infect Dis 2022;119:1-9. PMID 35339714
- 76
- Durand ML, Calderwood SB, Weber DJ, et al. Acute bacterial meningitis in adults. A review of 493 episodes. N Engl J Med 1993;328(1):21-8. PMID 8416268
- 77
- Duval X, Taha MK, Lamaury I, et al. One-year sequelae and quality of life in adults with meningococcal meningitis: lessons from the COMBAT multicentre prospective study. Adv Ther 2022;39(6):3031-41. PMID 35484469
- 78
- Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. Lancet Infect Dis 2010;10(5):317-28. PMID 20417414
- 79
- Eriksson L, Johannesen TB, Stenmark B, et al. Genetic variants linked to the phenotypic outcome of invasive disease and carriage of Neisseria meningitidis. Microb Genom 2023;9(10):001124. PMID 37874326
- 80
- Evans JR, Artenstein MS, Hunter DH. Prevalence of meningococcal serogroups and description of three new groups. Am J Epidemiol 1968;87(3):643-6. PMID 4968345
- 81
- Fernandez K, Lingani C, Aderinola OM, et al. Meningococcal meningitis outbreaks in the African meningitis belt after meningococcal serogroup A conjugate vaccine introduction, 2011-2017. J Infect Dis 2019;220(Supplement_4):S225-S32. PMID 31671449
- 82
- Finne J, Leinonen M, Mäkelä PH. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet 1983;2(8346):355-7. PMID 6135869
- 83
- Fischer M, Hedberg K, Cardosi P, et al. Tobacco smoke as a risk factor for meningococcal disease. Pediatr Infect Dis J 1997;16(10):979-83. PMID 9380476
- 84
- Fitzpatrick PE, Salmon RL, Hunter PR, Roberts RJ, Palmer SR. Risk factors for carriage of Neisseria meningitidis during an outbreak in Wales. Emerg Infect Dis 2000;6(1):65-9. PMID 10653573
- 85
- Fletcher LD, Bernfield L, Barniak V, et al. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect Immun 2004;72(4):2088-100. PMID 15039331
- 86
- Gandhi A, Balmer P, York LJ. Characteristics of a new meningococcal serogroup B vaccine, bivalent rLP2086 (MenB-FHbp; Trumenba®). Postgrad Med 2016;128(6):548-56. PMID 27467048
- 87
- Gasparini R, Conversano M, Bona G, et al. Randomized trial on the safety, tolerability, and immunogenicity of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, administered concomitantly with a combined tetanus, reduced diphtheria, and acellular pertussis vaccine in adolescents and young adults. Clin Vaccine Immunol 2010;17(4):537-44. PMID 20164251
- 88
- GBD 2019 Meningitis Antimicrobial Resistance Collaborators. Global, regional, and national burden of meningitis and its aetiologies, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol 2023;22(8):685-711. PMID 37479374
- 89
- Girard MP, Preziosi MP, Aguado MT, Kieny MP. A review of vaccine research and development: meningococcal disease. Vaccine 2006;24(22):4692-700. PMID 16621189
- 90
- Girgis N, Sultan Y, Frenck RW Jr, El-Gendy A, Farid Z, Matezcun A. Azithromycin compared with rifampin for eradication of nasopharyngeal colonization by Neisseria meningitidis. Pediatr Infect Dis J 1998;17:816-9. PMID 9779768
- 91
- Goldacre MJ, Wotton CJ, Maisonneuve JJ. Maternal and perinatal factors associated with subsequent meningococcal, Haemophilus or enteroviral meningitis in children: database study. Epidemiol Infect 2014;142(2):371-8. PMID 23659618
- 92
- Griffith CPC. The diseases of infants and children. Vol. 1. Philadelphia, London: W.B. Saunders Company, 1919.
- 93
- Gupta S, Tuladhar AB. Does early administration of dexamethasone improve neurological outcome in children with meningococcal meningitis. Arch Dis Chil 2004;89:82-3. PMID 14709520
- 94
- Hansen J, Zhang L, Eaton A, et al. Post-licensure safety surveillance study of routine use of quadrivalent meningococcal diphtheria toxoid conjugate vaccine (MenACWY-D) in infants and children. Vaccine 2018;36(16):2133-8. PMID 29550195
- 95
- Harrison LH. A multivalent conjugate vaccine for prevention of meningococcal disease in infants. JAMA 2008;299:217-9. PMID 18182606
- 96
- Harrison LH. Epidemiological profile of meningococcal disease in the United States. Clin Infect Dis 2010;50 Suppl 2:S37-44. PMID 20144015
- 97
- Harrison LH, Shutt KA, Schmink SE, et al. Population structure and capsular switching of invasive Neisseria meningitidis isolates in the pre-meningococcal conjugate vaccine era--United States, 2000-2005. J Infect Dis 2010;201(8):1208-24. PMID 20199241
- 98
- Harrison OB, Claus H, Jiang Y, et al. Description and nomenclature of Neisseria meningitidis capsule locus. Emerg Infect Dis 2013;19(4):566-73. PMID 23628376
- 99
- Heckenberg SG, Brouwer MC, van der Ende A, van de Beek D. Adjunctive dexamethasone in adults with meningococcal meningitis. Neurology 2012;79(15):1563-9. PMID 22972648
- 100
- Heckenberg SG, de Gans J, Brouwer MC, et al. Clinical features, outcome, and meningococcal genotype in 258 adults with meningococcal meningitis: a prospective cohort study. Medicine (Baltimore) 2008;87(4):185-92. PMID 18626301
- 101
- Hellerud BC, Aase A, Herstad TK, et al. Critical roles of complement and antibodies in host defense mechanisms against Neisseria meningitidis as revealed by human complement genetic deficiencies. Infect Immun 2010;78(2):802-9. PMID 19933829
- 102
- Herrera-Restrepo O, Zhou Z, Krishnan A, et al. Awareness, attitudes, and practices on meningococcal serogroup B vaccination in the United States among parents of older adolescents and among young adults. Curr Med Res Opin 2024;40(1):125-40. PMID 38032143
- 103
- Hill DJ, Griffiths NJ, Borodina E, Virji M. Cellular and molecular biology of Neisseria meningitidis colonization and invasive disease. Clin Sci (Lond) 2010;118(9):547-64. PMID 20132098
- 104
- Hoebe CJ, de Melker H, Spanjaard L, Dankert J, Nagelkerke N. Space-time cluster analysis of invasive meningococcal disease. Emerg Infect Dis 2004;10:1621-6. PMID 15498165
- 105
- Hovmand N, Christensen HC, Lundbo LF, et al. Nonspecific symptoms dominate at first contact to emergency healthcare services among cases with invasive meningococcal disease. BMC Fam Pract 2021;22(1):240. PMID 34847878
- 106
- Huang HR, Chen HL, Chu SM. Clinical spectrum of meningococcal infection in infants younger than six months of age. Chang Gung Med J 2006;29(1):107-13. PMID 16642734
- 107
- Huang L, Fievez S, Goguillot M, et al. A database study of clinical and economic burden of invasive meningococcal disease in France. PLoS One 2022;17(4):e0267786. PMID 35486581
- 108
- Huels J, Clements KM, McGarry LJ, Hill GJ, Wassil J, Kessabi S. Modelled evaluation of multi-component meningococcal vaccine (Bexsero®) for the prevention of invasive meningococcal disease in infants and adolescents in the UK. Epidemiol Infect 2014;142(9):2000-12. PMID 24284038
- 109
- Irving TJ, Blyuss KB, Colijn C, Trotter CL. Modelling meningococcal meningitis in the African meningitis belt. Epidemiol Infect 2012;140(5):897-905. PMID 21781369
- 110
- Jaca A, Wiyeh AB, Sambala EZ, Wiysonge CS. The burden of meningococcal meningitis in the African meningitis belt, from 2009 to 2014: a trend analysis. Pan Afr Med J 2021;39:57. PMID 34422180
- 111
- Jackson LA, Wenger JD. Laboratory-based surveillance for meningococcal disease in selected areas, United States, 1989-1991. MMWR CDC Surveill Summ 1993;42(2):21-30. PMID 8510639
- 112
- Jen FE, Abrahams JL, Schulz BL, Lamelas A, Pluschke G, Jennings MP. High-frequency changes in pilin glycosylation patterns during Neisseria meningitidis serogroup a meningitis outbreaks in the African meningitis belt. ACS Infect Dis 2023;9(8):1451-7. PMID 37467082
- 113
- Jiang HQ, Hoiseth SK, Harris SL, et al. Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. Vaccine 2010;28(37):6086-93. PMID 20619376
- 114
- Johswich KO, McCaw SE, Islam E, et al. In vivo adaptation and persistence of Neisseria meningitidis within the nasopharyngeal mucosa. PLoS Pathog 2013;9(7):e1003509. PMID 23935487
- 115
- Kaplan SL, Schutze GE, Leake JA, et al. Multicenter surveillance of invasive meningococcal infections in children. Pediatrics 2006;118(4):e979-84. PMID 17015517
- 116
- Karsany MS, Elshayeb AA, Saeed ES, et al. Patterns of meningococcal infection in Sudan with emergence of Neisseria meningitidis serogroup W135. East Mediterr Health J 2013;19(10):843-6. PMID 24313147
- 117
- Khatami A, Pollard AJ. The epidemiology of meningococcal disease and the impact of vaccines. Expert Rev Vaccines 2010;9(3):285-98. PMID 20218857
- 118
- Konar M, Granoff DM, Beernink PT. Importance of inhibition of binding of complement factor H for serum bactericidal antibody responses to meningococcal factor H-binding protein vaccines. J Infect Dis 2013;208(4):627-36. PMID 23715659
- 119
- Koplik H. The diseases of infancy and childhood designed for the use of students and practitioners of medicine. Fourth edition. Philadelphia and New York: Lea & Fibinger, 1918.
- 120
- Krause G, Blackmore C, Wiersma S, Lesneski C, Gauch L, Hopkins RS. Mass vaccination campaign following community outbreak of meningococcal disease. Emerg Infect Dis 2002;8(12):1398-403. PMID 12498654
- 121
- Ladhani SN, Cordery R, Mandal S, et al. Preventing secondary cases of invasive meningococcal capsular group B (MenB) disease using a recently-licensed, multi-component, protein-based vaccine (Bexsero(®)). J Infect 2014;69(5):470-80. PMID 25043395
- 122
- LaForce FM, Okwo-Bele JM. Eliminating epidemic Group A meningococcal meningitis in Africa through a new vaccine. Health Aff (Millwood) 2011;30(6):1049-57. PMID 21653956
- 123
- LaForce FM, Ravenscroft N, Djingarey M, Viviani S. Epidemic meningitis due to Group A Neisseria meningitidis in the African meningitis belt: a persistent problem with an imminent solution. Vaccine 2009;27 Suppl 2:B13-9. PMID 19477559
- 124
- Laribiere A, Miremont-Salame G, Reyre H, et al. Surveillance of adverse effects during a vaccination campaign against meningitis C. Eur J Clin Pharmacol 2005;61(12):907-11. PMID 16328316
- 125
- Levi M, Donzellini M, Varone O, et al. Surveillance of adverse events following immunization with meningococcal group C conjugate vaccine: Tuscany, 2005-2012. J Prev Med Hyg 2014;55(4):145-51. PMID 26137788
- 126
- Lo H, Tang CM, Exley RM. Mechanisms of avoidance of host immunity by Neisseria meningitidis and its effect on vaccine development. Lancet Infect Dis 2009;9(7):418-27. PMID 19555901
- 127
- Loh E, Kugelberg E, Tracy A, et al. Temperature triggers immune evasion by Neisseria meningitidis. Nature 2013;502(7470):237-40. PMID 24067614
- 128
- Lu PJ, Jain N, Cohn AC. Meningococcal conjugate vaccination among adolescents aged 13-17 years, United States, 2007. Vaccine 2010;28(11):2350-5. PMID 20044055
- 129
- Luo Y, Friese OV, Runnels HA, et al. The dual role of lipids of the lipoproteins in Trumenba, a self-adjuvanting vaccine against meningococcal meningitis B disease. AAPS J 2016;18(6):1562-75. PMID 27604766
- 130
- Maiden MC. The impact of protein-conjugate polysaccharide vaccines: an endgame for meningitis. Philos Trans R Soc Lond B Biol Sci 2013;368(1623):20120147. PMID 23798695
- 131
- Mairey E, Genovesio A, Donnadieu E, et al. Cerebral microcirculation shear stress levels determine Neisseria meningitides attachment sites along the blood-brain barrier. J Exp Med 2006;203(8):1939-50. PMID 16864659
- 132
- Martin NG, Sadarangani M, Pollard AJ, Goldacre MJ. Hospital admission rates for meningitis and septicaemia caused by Haemophilus influenzae, Neisseria meningitidis, and Streptococcus pneumoniae in children in England over five decades: a population-based observational study. Lancet Infect Dis 2014;14(5):397-405. PMID 24631222
- 133
- Martinon-Torres F, Banzhoff A, Azzari C, et al. Recent advances in meningococcal B disease prevention: real-world evidence from 4CMenB vaccination. J Infect 2021;83(1):17-26. PMID 33933528
- 134
- Marshall HS, Richmond PC, Nissen MD, et al. Safety and immunogenicity of a meningococcal B bivalent rLP2086 vaccine in healthy toddlers aged 18-36 months: a phase 1 randomized-controlled clinical trial. Pediatr Infect Dis J 2012;31(10):1061-8. PMID 22718089
- 135
- Martinon-Torres F, Gimenez-Sanchez F, Bernaola-Iturbe E, Diez-Domingo J, Jiang Q, Perez JL. A randomized, phase 1/2 trial of the safety, tolerability, and immunogenicity of bivalent rLP2086 meningococcal B vaccine in healthy infants. Vaccine 2014;32(40):5206-11. PMID 25077420
- 136
- Mayer LW, Reeves MW, Al-Hamdan N, et al. Outbreak of W135 meningococcal disease in 2000: not emergence of a new W135 strain but clonal expansion within the electrophoretic type-37 complex. J Infect Dis 2002;185:1596-605. PMID 12023765
- 137
- Mazamay S, Guégan JF, Diallo N, et al. An overview of bacterial meningitis epidemics in Africa from 1928 to 2018 with a focus on epidemics "outside-the-belt." BMC Infect Dis 2021;21(1):1027.** PMID 34592937
- 138
- Mbaeyi SA, Bozio CH, Duffy J, et al. Meningococcal vaccination: recommendations of the Advisory Committee on Immunization Practices, United States, 2020. MMWR Recomm Rep 2020;69(9):1-41. PMID 33417592
- 139
- McIntyre P. Should dexamethasone be part of routine therapy of bacterial meningitis in industrialized countries. Adv Exp Med Biol 2005;568:189-97. PMID 16107073
- 140
- McNamara LA, Shumate AM, Johnsen P, et al. First use of a serogroup B meningococcal vaccine in the US in response to a university outbreak. Pediatrics 2015;135(5):798-804. PMID 25917990
- 141
- McNeil LK, Murphy E, Zhao XJ, et al. Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide. Vaccine 2009;27(25-26):3417-21. PMID 19200847
- 142
- Mehlhorn AJ, Balcer HE, Sucher BJ. Update on prevention of meningococcal disease: focus on tetravalent meningococcal conjugate vaccine. Ann Pharmacother 2006;40(4):666-73. PMID 16595570
- 143
- Meiring S, Tempia S, Dominic EM, et al. Excess invasive meningococcal disease associated with seasonal influenza, South Africa, 2003-2018. Clin Infect Dis 2022;74(10):1729-35. PMID 34389845
- 144
- Memish ZA, Goubeaud A, Bröker M, Malerczyk C, Shibl AM. Invasive meningococcal disease and travel. J Infect Public Health 2010;3(4):143-51. PMID 21126718
- 145
- MenAfriCar Consortium. Meningococcal carriage in the African meningitis belt. Trop Med Int Health 2013;18(8):968-78. PMID 23682910
- 146
- MenAfriCar Consortium. The diversity of meningococcal carriage across the African meningitis belt and the impact of vaccination with a group a meningococcal conjugate vaccine. J Infect Dis 2015;212(8):1298-307. PMID 25858956
- 147
- Mendum TA, Newcombe J, McNeilly CL, McFadden J. Towards the immunoproteome of Neisseria meningitidis. PLoS One 2009;4(6):e5940. PMID 19529772
- 148
- Micoli F, Romano MR, Tontini M, et al. Development of a glycoconjugate vaccine to prevent meningitis in Africa caused by meningococcal serogroup X. Proc Natl Acad Sci U S A 2013;110(47):19077-82. PMID 24191022
- 149
- Mikucki A, McCluskey NR, Kahler CM. The host-pathogen interactions and epicellular lifestyle of Neisseria meningitidis. Front Cell Infect Microbiol 2022;12:862935. PMID 35531336
- 150
- Mohammed I, Iliyasu G, Habib AG. Emergence and control of epidemic meningococcal meningitis in sub-Saharan Africa. Pathog Glob Health 2017;111(1):1-6. PMID 28081671
- 151
- Mongelluzzo J, Mohamad Z, Ten Have TR, Shah SS. Corticosteroids and mortality in children with bacterial meningitis. JAMA 2008;299(17):2048-55. PMID 18460665
- 152
- Mothershed EA, Sacchi CT, Whitney AM, et al. Use of real-time PCR to resolve slide agglutination discrepancies in serogroup identification of Neisseria meningitidis. J Clin Microbiol 2004;42:320-8. PMID 14715772
- 153
- Moura AS, Pablos-Mendez A, Layton M, Weiss D. Epidemiology of meningococcal disease, New York City, 1989-2000. Emerg Infect Dis 2003;9(3):355-61. PMID 12643832
- 154
- Mueller JE, Yaro S, Njanpop-Lafourcade BM, et al. Study of a localized meningococcal meningitis epidemic in Burkina Faso: incidence, carriage, and immunity. J Infect Dis 2011;204(11):1787-95. PMID 21998478
- 155
- Murphy E, Andrew L, Lee KL, et al. Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J Infect Dis 2009;200(3):379-89. PMID 19534597
- 156
- Nakamura T, Cohen AL, Schwartz S, et al. The global landscape of pediatric bacterial meningitis data reported to the World Health Organization-coordinated Invasive Bacterial Vaccine-Preventable Disease Surveillance Network, 2014-2019. J Infect Dis 2021;224(12 Suppl 2):S161-73. PMID 34469555
- 157
- Nanduri S, Foo C, Ngo V, et al. Outbreak of serogroup c meningococcal disease primarily affecting men who have sex with men - Southern California, 2016. MMWR Morb Mortal Wkly Rep 2016;65(35):939-40. PMID 27606798
- 158
- Nathan N, Borel T, Djibo A, et al. Ceftriaxone as effective as long-acting chloramphenicol in short-course treatment of meningococcal meningitis during epidemics: a randomized non-inferiority study. Lancet 2005;366:308-13. PMID 16039333
- 159
- Nissen MD, Marshall HS, Richmond PC, et al. A randomized, controlled, phase 1/2 trial of a Neisseria meningitides serogroup B bivalent rLP2086 vaccine in healthy children and adolescents. Pediatr Infect Dis J 2013;32(4):364-71. PMID 23114369
- 160
- O'Brien JA, Caro JJ, Getsios D. Managing meningococcal disease in the United States: Hospital case characteristics and costs by age. Value Health 2006;9(4):236-43. PMID 16903993
- 161
- Offit PA, Peter G. The meningococcal vaccine--public policy and individual choices. N Engl J Med 2003;349(24):2353-6. PMID 14668463
- 162
- Offit PA, Peter G. Meningococcal conjugate vaccine in the UK: an update. Lancet 2004;364(9431):309-10. PMID 15276371
- 163
- Ohm M, Hahné SJM, van der Ende A, et al. Vaccine impact and effectiveness of meningococcal serogroup ACWY conjugate vaccine implementation in the Netherlands: a nationwide surveillance study. Clin Infect Dis 2022;74(12):2173-80. PMID 34525199
- 164
- Okike IO, Ribeiro S, Ramsay ME, Heath PT, Sharland M, Ladhani SN. Trends in bacterial, mycobacterial, and fungal meningitis in England and Wales 2004-11: an observational study. Lancet Infect Dis 2014;14(4):301-7. PMID 24508198
- 165
- Orr HJ, Gray SJ, Macdonald M, Stuart JM. Saliva and meningococcal transmission. Emerg Infect Dis 2003;9(10):1314-5. PMID 14609470
- 166
- Pillai S, Howell A, Alexander K, et al. Outer membrane protein (OMP) based vaccine for Neisseria meningitides serogroup B. Vaccine 2005;23(17-18):2206-9. PMID 15755596
- 167
- Pizza M, Donnelly J, Rappuoli R. Factor H-binding protein, a unique meningococcal vaccine antigen. Vaccine 2008;26 Suppl 8:I46-8. PMID 19388164
- 168
- Pace D, Khatami A, McKenna J, et al. Immunogenicity of reduced dose priming schedules of serogroup C meningococcal conjugate vaccine followed by booster at 12 months in infants: open label randomised controlled trial. BMJ 2015;350:h1554. PMID 25832102
- 169
- Parikh SR, Campbell H, Bettinger JA, et al. The everchanging epidemiology of meningococcal disease worldwide and the potential for prevention through vaccination. J Infect 2020;81(4):483-98. PMID 32504737
- 170
- Patel M, Lee CK. Polysaccharide vaccines for preventing serogroup A meningococcal meningitis. Cochrane Database Syst Rev 2005;(1):CD001093. PMID 15674874
- 171
- Perrett KP, Pollard AJ. Towards an improved serogroup B Neisseria meningitidis vaccine. Expert Opin Biol Ther 2005;5(12):1611-25. PMID 16318425
- 172
- Purcell B, Samuelsson S, Hahne SJ, et al. Effectiveness of antibiotics in preventing meningococcal disease after a case: systematic review. BMJ 2004;328(7452):1339. PMID 15178612
- 173
- Quagliarello VJ, Scheld WM. Treatment of bacterial meningitis. N Engl J Med 1997;336(10):708-16. PMID 9041103
- 174
- Ramsay ME, Andrews NJ, Trotter CL, Kaczmarski EB, Miller E. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ 2003;326(7385):365-6. PMID 12586669
- 175
- Read RC, Baxter D, Chadwick DR, et al. Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial. Lancet 2014;384(9960):2123-31. PMID 25145775
- 176
- Read RC, Zimmerli S, Broaddus C, Sanan DA, Stephens DS, Ernst JD. The (alpha2-->8)-linked polysialic acid capsule of group B Neisseria meningitidis modifies multiple steps during interaction with human macrophages. Infect Immun 1996;64(8):3210-7. PMID 8757855
- 177
- Reese HE, Ronveaux O, Mwenda JM, et al. Invasive meningococcal disease in Africa's meningitis belt: more than just meningitis? J Infect Dis 2019;220(Supplement 4):S263-5. PMID 31671435
- 178
- Richmond PC, Nissen MD, Marshall HS, et al. A bivalent Neisseria meningitidis recombinant lipidated factor H binding protein vaccine in young adults: results of a randomised, controlled, dose-escalation phase 1 trial. Vaccine 2012;30(43):6163-74. PMID 22871351
- 179
- Robertson CA, Oster P, Johnson DR, Reinhardt A, Greenberg D, Decker MD. Prevention of invasive meningococcal disease in the United States: current state of the art. J Vaccines Vaccin 2013;4:211.
- 180
- Rosenstein NE, Perkins BA, Stephens DS, et al. The changing epidemiology of meningococcal disease in the United States, 1992-1996. J Infect Dis 1999;180(6):1894-901. PMID 10558946
- 181
- Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal disease. N Engl J Med 2001;344(18):1378-88. PMID 11333996
- 182
- Sadarangani M, Scheifele DW, Halperin SA, et al. The impact of the meningococcal serogroup C conjugate vaccine in Canada between 2002 and 2012. Clin Infect Dis 2014;59(9):1208-15. PMID 25069868
- 183
- Sanders MS, van Well GT, Ouburg S, Lundberg PS, van Furth AM, Morré SA. Single nucleotide polymorphisms in TLR9 are highly associated with susceptibility to bacterial meningitis in children. Clin Infect Dis 2011;52(4):475-80. PMID 21258099
- 184
- Schneider MC, Exley RM, Ram S, Sim RB, Tang CM. Interactions between Neisseria meningitidis and the complement system. Trends Microbiol 2007;15(5):233-40. PMID 17398100
- 185
- Schuchat A, Robinson K, Wenger JD, et al. Bacterial meningitis in the United States in 1995. Active Surveillance Team. N Engl J Med 1997;337(14):970-6. PMID 9395430
- 186
- Seib KL, Scarselli M, Comanducci M, Toneatto D, Masignani V. Neisseria meningitidis factor H-binding protein fHbp: a key virulence factor and vaccine antigen. Expert Rev Vaccines 2015;14(6):841-59. PMID 25704037
- 187
- Seib KL, Serruto D, Oriente F, et al. Factor H-binding protein is important for meningococcal survival in human whole blood and serum and in the presence of the antimicrobial peptide LL-37. Infect Immun 2009;77(1):292-9. PMID 18852235
- 188
- Serruto D, Spadafina T, Ciucchi L, et al. Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans. Proc Natl Acad Sci U S A 2010;107(8):3770-5. PMID 20133713
- 189
- Sharip A, Sorvillo F, Redelings MD, Mascola L, Wise M, Nguyen DM. Population-based analysis of meningococcal disease mortality in the United States: 1990-2002. Pediatr Infect Dis J 2006;25(3):191-4. PMID 16511378
- 190
- Sheldon EA, Schwartz H, Jiang Q, Giardina PC, Perez JL. A phase 1, randomized, open-label, active-controlled trial to assess the safety of a meningococcal serogroup B bivalent rLP2086 vaccine in healthy adults. Hum Vaccin Immunother 2012;8(7):888-95. PMID 22832260
- 191
- Sibomana O, Hakayuwa CM. The meningitis outbreak returns to Niger: concern, efforts, challenges, and recommendations. Immun Inflamm Dis 2023;11(7):e953. PMID 37506148
- 192
- Sidikou F, Potts CC, Zaneidou M, et al. Epidemiology of bacterial meningitis in the nine years since meningococcal serogroup A conjugate vaccine introduction, Niger, 2010-2018. J Infect Dis 2019;220(Supplement_4):S206-15. PMID 31671439
- 193
- Smith I, Bjornevik AT, Augland IM, Berstad A, Wentzel-Larsen T, Halstensen A. Variations in case fatality and fatality risk factors of meningococcal disease in Western Norway, 1985-2002. Epidemiol Infect 2006;134(1):103-10. PMID 16409656
- 194
- Smith JL. Cerebro-spinal fever. In: Keating JM, editor. Cyclopaedia of the diseases of children: medical and surgical: the articles written especially for the work by American, British, and Canadian authors. Vol. 1. Philadelphia: JB Lippincott Company, 1889:514-54.
- 195
- Snape MD, Perrett KP, Ford KJ, et al. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. JAMA 2008;299:173-84. PMID 18182599
- 196
- Sotir MJ, Ahrabi-Fard S, Croft DR, et al. Meningococcal disease incidence and mortality in Wisconsin, 1993-2002. WMJ 2005;104:38-44. PMID 15966631
- 197
- Sow SO, Okoko BJ, Diallo A, et al. Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans. N Engl J Med 2011;364(24):2293-304. PMID 21675889
- 198
- Stefanizzi P, Di Lorenzo A, Martinelli A, et al. Adverse events following immunization (AEFIs) with anti-meningococcus type B vaccine (4CMenB): data of post-marketing active surveillance program. Apulia Region (Italy), 2019-2023. Vaccine 2023;41(48):7096-102. PMID 37891052
- 199
- Stollenwerk N, Maiden MC, Jansen VA. Diversity in pathogenicity can cause outbreaks of meningococcal disease. Proc Natl Acad Sci U S A 2004;101(27):10229-34. PMID 15218099
- 200
- Sudarsanam TD, Rupali P, Tharyan P, Abraham OC, Thomas K. Pre-admission antibiotics for suspected cases of meningococcal disease. Cochrane Database Syst Rev 2013;8:CD005437. PMID 23908052
- 201
- Sultan B, Labadi K, Guégan JF, Janicot S. Climate drives the meningitis epidemics onset in West Africa. PloS Med 2005;2:43-9. PMID 15696216
- 202
- Swartz MN. Bacterial meningitis--a view of the past 90 years. N Engl J Med 2004;351(18):1826-8. PMID 15509815
- 203
- Taha MK, Achtman M, Alonso JM, et al. Serogroup W135 meningococcal disease in Hajj pilgrims. Lancet 2000;356:2159. PMID 11191548
- 204
- Taha MK, Bekkat-Berkani R, Abitbol V. Changing patterns of invasive meningococcal disease and future immunization strategies. Hum Vaccin Immunother 2023;19(1):2186111. PMID 37017273
- 205
- Taha MK, Parent Du Chatelet I, Schlumberger M, et al. Neisseria meningitides serogroups W135 and A were equally prevalent among meningitis cases occurring at the end of the 2001 epidemics in Burkina Faso and Niger. J Clin Microbiol 2002;40:1083-4. PMID 11880446
- 206
- Tan LK, Carlone GM, Borrow R. Advances in the development of vaccines against Neisseria meningitides. N Engl J Med 2010;362:1511-20. PMID 20410516
- 207
- Tan LL, Safadi MA, Horn M, et al. Pandemic's influence on parents' attitudes and behaviors toward meningococcal vaccination. Hum Vaccin Immunother 2023;19(1):2179840. PMID 36883777
- 208
- Tascini C, Iantomasi R, Sbrana F, et al. MAGLIO study: epideMiological Analysis on invasive meninGococcaL disease in Italy: fOcus on hospitalization from 2015 to 2019. Intern Emerg Med 2023;18(7):1961-9. PMID 37528328
- 209
- Teyssou R, Muros-Le Rouzic E. Meningitis epidemics in Africa: a brief overview. Vaccine 2007;25(Suppl 1):A3-7. PMID 17643560
- 210
- Thollot F, Scheifele D, Pankow-Culot H, et al. A randomized study to evaluate the immunogenicity and safety of a heptavalent diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, haemophilus influenzae b, and meningococcal serogroup C combination vaccine administered to infants at 2, 4 and 12 months of age. Pediatr Infect Dis J 2014;33(12):1246-54. PMID 25037033
- 211
- Thompson MJ, Ninis N, Perera R, et al. Clinical recognition of meningococcal disease in children and adolescents. Lancet 2006;367(9508):397-403. PMID 16458763
- 212
- Topaz N, Caugant DA, Taha MK, et al. Phylogenetic relationships and regional spread of meningococcal strains in the meningitis belt, 2011-2016. EBioMedicine 2019;41:488-96. PMID 30846392
- 213
- Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 2004;364(9431):365-7. PMID 15276396
- 214
- Tunio SA, Oldfield NJ, Ala'Aldeen DA, Wooldridge KG, Turner DP. The role of glyceraldehyde 3-phosphate dehydrogenase (GapA-1) in Neisseria meningitidis adherence to human cells. BMC Microbiol 2010a;10:280. PMID 21062461
- 215
- Tunio SA, Oldfield NJ, Berry A, Ala'Aldeen DA, Wooldridge KG, Turner DP. The moonlighting protein fructose-1, 6-bisphosphate aldolase of Neisseria meningitidis: surface localization and role in host cell adhesion. Mol Microbiol 2010b;76(3):605-15. PMID 20199602
- 216
- Tyrrell GJ, Chui L, Johnson M, et al. Outbreak of Neisseria meningitidis, Edmonton, Alberta, Canada. Emerg Infect Dis 2002;8(5):519-21. PMID 11996690
- 217
- Tzanakaki G, Cabrnochová H, Delić S, et al. Invasive meningococcal disease in South-Eastern European countries: do we need to revise vaccination strategies? Hum Vaccin Immunother 2024;20(1):2301186. PMID 38173392
- 218
- van de Beek D, de Gans J, McIntyre P, Prasad K. Steroids in adults with acute bacterial meningitis: a systematic review. Lancet Infect Dis 2004a;4:139-43. PMID 14998499
- 219
- van de Beek D, de Gans J, McIntyre P, Prasad K. Corticosteroids for acute bacterial meningitis. Cochrane Database Syst Rev 2007a;(1):CD004405. PMID 17253505
- 220
- van de Beek D, de Gans J, Spanjaard L, Weisfelt M, Reitsma JB, Vermeulen M. Clinical features and prognostic factors in adults with bacterial meningitis. N Engl J Med 2004b;351(18):1849-59. PMID 15509818
- 221
- van de Beek D, de Gans J, Tunkel AR, Wijdicks EF. Community-acquired bacterial meningitis in adults. N Engl J Med 2006;354(1):44-53. PMID 16394301
- 222
- van de Beek D, Patel R, Wijdicks EF. Meningococcal meningitis with brainstem infarction. Arch Neurol 2007b;64:1350-1. PMID 17846279
- 223
- van Kessel F, van den Ende C, Oordt-Speets AM, Kyaw MH. Outbreaks of meningococcal meningitis in non-African countries over the last 50 years: a systematic review. J Glob Health 2019;9(1):010411. PMID 30937163
- 224
- Viner RM, Booy R, Johnson H, et al. Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study. Lancet Neurol 2012;11(9):774-83. PMID 22863608
- 225
- Visintin C, Mugglestone MA, Fields EJ, Jacklin P, Murphy MS, Pollard AJ; Guideline Development Group; National Institute for Health and Clinical Excellence. Management of bacterial meningitis and meningococcal septicaemia in children and young people: summary of NICE guidance. BMJ 2010;340:c3209. PMID 20584794
- 226
- Walter S, Gil-Prieto R, Gil-Conesa M, Rodriguez-Caravaca G, San Román J, Gil de Miguel A. Hospitalizations related to meningococcal infection in Spain from 1997 to 2018. BMC Infect Dis 2021;21(1):1215. PMID 34872512
- 227
- Wang X, Shutt KA, Vuong JT, et al. Changes in the population structure of invasive Neisseria meningitidis in the United States after quadrivalent meningococcal conjugate vaccine licensure. J Infect Dis 2015;211(12):1887-94. PMID 25556253
- 228
- Whisnant J, Martin-Kerry J, Flett L, Knapp P. Predictors of meningococcal vaccine uptake in university and college students: a systematic review and meta-analysis. J Am Coll Health 2022;70(6):1738-53. PMID 33048644
- 229
- Wilder-Smith A. Meningococcal vaccine in travelers. Curr Opin Infect Dis 2007;20:454-60. PMID 17762777
- 230
- Wilkins AL, Snape MD. Emerging clinical experience with vaccines against group B meningococcal disease. Vaccine 2018;36(36):5470-6. PMID 28778616
- 231
- Willerton L, Lucidarme J, Walker A, et al. Antibiotic resistance among invasive Neisseria meningitidis isolates in England, Wales and Northern Ireland (2010/11 to 2018/19). PLoS One 2021;16(11):e0260677. PMID 34843604
- 232
- Williams CJ, Willocks LJ, Lake IR, Hunter PR. Geographic correlation between deprivation and risk of meningococcal disease: an ecological study. BMC Public Health 2004;4:30. PMID 15274745
- 233
- World Health Organization. Epidemics of meningococcal disease: African meningitis belt, 2001. Wkly Epidemiol Rec 2001;76(37):282-8. PMID 11577498
- 234
- World Health Organization. WHO position paper, Meningococcal A conjugate vaccine: Updated guidance, February 2015. Vaccine 2018;36(24):3421-2. PMID 28760613
- 235
- Xie O, Pollard AJ, Mueller JE, Norheim G. Emergence of serogroup X meningococcal disease in Africa: need for a vaccine. Vaccine 2013;31(27):2852-61. PMID 23623866
- 236
- Yezli S. The threat of meningococcal disease during the Hajj and Umrah mass gatherings: a comprehensive review. Travel Med Infect Dis 2018;24:51-8. PMID 29751133
- 237
- Zimmer SM, Stephens DS. Meningococcal conjugate vaccines. Expert Opin Pharmacother 2004;5:855-63. PMID 15102568
Contributors
All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.
Author
-
Douglas J Lanska MD MS MSPH
Dr. Lanska of the University of Wisconsin School of Medicine and Public Health and the Medical College of Wisconsin has no relevant financial relationships to disclose.
See Profile
Patient Profile
- Age range of presentation
-
- 0 month to 65+ years
- Sex preponderance
-
- male=female
- Heredity
-
- none
- Population groups selectively affected
-
- Blacks
- Occupation groups selectively affected
-
- none selectively affected
ICD & OMIM codes
- ICD-10
-
- Meningococcal infection: A39
- Meningococcal meningitis: A39.0 + G01
- Meningococcal encephalitis: A39.8 + G05.0
- Meningococcaemia: A39.4
- Waterhouse-Friderichsen syndrome, meningococcal: A39.1 + E35.1
- Meningococcal carditis: A39.5 + I52.0
- Other specified meningococcal infections: A39.8
- Meningococcal infection, unspecified: A39.9
- ICD-11
-
- Meningococcal disease: 1C1C
- Meningococcal meningitis: 1C1C.0
- Waterhouse-Friderichsen syndrome: 1C1C.1
- Meningococcaemia: 1C1C.2
- Other specified meningococcal disease: 1C1C.Y
This is an article preview.
Start a Free Account
to access the full version.
-
Nearly 3,000 illustrations, including video clips of neurologic disorders.
-
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
-
Full spectrum of neurology in 1,200 comprehensive articles.
-
Listen to MedLink on the go with Audio versions of each article.
Questions or Comment?
MedLink®, LLC
3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122
Toll Free (U.S. + Canada): 800-452-2400
US Number: +1-619-640-4660
Support: service@medlink.com
Editor: editor@medlink.com
ISSN: 2831-9125
Also in This Category
-
-
Infectious Disorders
Genital herpes: neurologic complications
Nov. 15, 2024
-
General Child Neurology
Acute cerebellar ataxia in children
Oct. 29, 2024
-
Infectious Disorders
Zika virus: neurologic complications
Oct. 08, 2024
-
General Child Neurology
Cerebral edema in childhood
Sep. 29, 2024
-
Neuro-Oncology
CNS germinoma
Sep. 25, 2024
-
Developmental Malformations
Vein of Galen malformations
Sep. 22, 2024
-
Infectious Disorders
Gram-negative bacillary meningitis
Sep. 13, 2024